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resumo 
 
 
O cancro é uma das doenças com maior ocorrência na população mundial e com uma 
elevada taxa de mortalidade. Os principais problemas na luta contra o cancro prendem-
se com a dificuldade de diagnóstico precoce, a citotoxicidade associada aos fármacos 
anticancerígenos usados em quimioterapia convencional e a falta de tratamentos mais 
eficazes. Com o advento da nanotecnologia, tem havido um crescente interesse na 
aplicação de nanopartículas e nanoestruturas, nas mais diversas áreas da ciência, 
nomeadamente em aplicações biomédicas. Neste contexto em particular, as 
nanopartículas magnéticas apresentam propriedades interessantes, por exemplo, em 
sistemas de libertação controlada de fármaco e em hipertermia. A sua aplicação em áreas 
relacionadas com a saúde, como o tratamento de cancro por hipertermia magnética, passa 
necessariamente por uma boa caracterização das suas propriedades e pela correta 
avaliação das suas capacidades de libertação de energia sob a forma de calor por indução 
magnética. 
Nesse sentido, este trabalho teve como objetivo a síntese de nanopartículas de magnetite 
devido a sua compatibilidade com o organismo humano e propriedades magnéticas. No 
entanto, devido ao seu elevado grau de agregação assim como facilidade de oxidação em 
meios aquosos existe uma necessidade de revestir estas partículas. Para tal, foi utilizado 
um biopolímero: a quitosana.  
A ligação do revestimento da quitosana ao núcleo do óxido de ferro foi realizada através 
de dois tipos de ancoragem: através da dopamina, conhecida pela sua grande afinidade 
aos grupos aminas e através do ácido cafeico, por apresentar uma similaridade estrutural 
à dopamina.  
Para a caracterização estrutural e morfológica das partículas recorreu-se à difração de 
raios-X (DRX), à espetroscopia de infravermelhos com transformada de Fourier (FTIR), 
à dispersão dinâmica da luz (DLS), ao Potencial Zeta e à microscopia eletrónica de 
transmissão (TEM). As propriedades magnéticas foram medidas por magnetometria de 
SQUID (Superconducting Quantum Interferance Device). Por fim foi avaliada a 
capacidade das partículas sintetizadas para aplicação em hipertermia magnética. 
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abstract Cancer is a disease with high incidence in the world population and equally with a high 
mortality rate. The main problems in the fight against cancer are linked to the difficulty 
of early diagnosis, the cytotoxicity associated with anticancer drugs used in conventional 
chemotherapy and the lack of more effective treatments. With the advent of 
nanotechnology, there has been increasing interest in the application of nanoparticles and 
nanostructures, in several areas of science, such as biomedicine. In this context, the 
magnetic nanoparticles have interesting properties in controlled drug release systems and 
hyperthermia. Its application in areas related to health, such as the treatment of cancer by 
magnetic hyperthermia, necessarily requires a good characterization of their properties 
and the correct assessment of their ability to release energy in the form of heat by 
magnetic induction. 
Therefore, this study aimed the synthesis of nanoparticles of magnetite due to their 
biocompatibility and magnetic properties. However, due to their high degree of 
aggregation as well as facile oxidation in aqueous media there is a need to coat these 
particles. For this purpose, a biopolymer was used: chitosan. The binding of the coat to 
the core of the iron oxide was accomplishment through two types of anchorages 
molecules: dopamine, knowing for their great affinity with amine groups and through 
caffeic acid due to structural similarity to dopamine. 
The structural and morphological characterization was performed using X-ray diffraction 
(DRX), Fourier transformed infrared spectroscopy (FTIR), dynamic light scattering 
(DLS), Zeta Potential; thermalgravimetric analysis and transmission electron microscopy 
(TEM). The magnetic properties were studied using a Superconducting Quantum 
Interference Device (SQUID) magnetometer. Finally, we evaluated the ability of some 
of the synthesized NPs for use in magnetic hyperthermia. 
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Introduction 
1.1Context 
 
In spite of all progress made in medicine, cancer remains as one of the largest global 
problem,  representing the main cause of illness and mortality worldwide.1  World Cancer 
Report 2014 predicted an increase of cancer events from 14, in 2012, to 22 millions within 
the next two decades.2 Only in 2012 more than 8 millions people died as consequence of a 
cancer.1  Moreover, in the report “Assessing national capacity for the prevention and control 
of noncommunicable diseases: global survey” concerning the period 2010–2015, the 160 
countries with available data saw an increase from 47 to 63% in number of cases of cancer 
incidence.3 According to World Health Organization (WHO), the most frequent types of 
cancers causing deaths are lung, liver, stomach, colorectal, breast and oesophageal.1 
Such overwhelming scenario, not only have impact in the huge number of human life losses, 
but also in the financial costs associated to treatments and palliative cares. According to a 
2015 report published in Forbes magazine, the global cancer drug market reached the US 
$100 billion mark in that year, and it is predicted to achieve to US $147 billion by 2018.4 
These appalling numbers reveal the huge need for further research exploring better, safer, 
and more effective therapeutic and diagnostic strategies than the used so far, enhancing 
patient’s life quality as well as extending their lifetime. The last decades were characterized 
by development of novel and advanced strategies to fight cancer illness. The conventional 
strategies commonly employed include surgery, chemotherapy, radiotherapy, stem cell 
transplant therapy, immunotherapy, and other varieties of targeted therapies.4 Despite the 
considerable progress in the developing cancer therapeutics, their harmful side effects are of 
dominant concern. Osteoporosis, infertility, premature ovarian failure, typhlitis, hair loss, 
herpesviridae infections, heart diseases, gastrointestinal lesions, gastric pain are few 
examples of possible side effects of the current therapies.4 One of the most worrying side 
effects is the resistance that tumour can acquire from the recurrent use of chemotherapeutic 
agents in therapies.5,6 
In an attempt to improve human’s health, nanotechnology applied to medicine has been 
proposed in the last decades.7 Nanomedicine, allows to work at molecular and cellular levels, 
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having the potential to achieve important developments in healthcare.8 The nanomaterials 
have been in the few years a remarkable role in cancer diagnostic and therapeutic, where the 
magnetic nanoparticles (MNPs) have been in the spotlight due to their unique properties.7–9 
MNPs easily match with biomolecules and can be manipulated, for example, by an external 
magnetic gradient,10 being used for magnetic resonance imaging as contrast agents,11–15 or 
they can be applied as drug delivery carriers14,16–18 for localized chemotherapy, for 
bioseparation,19–21 tissue repairing22 and thermal tumour therapy.23–26 
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1.2 Literature Review 
1.2.1. Cancer 
 
Cancer is characterized by abnormal cell growth9 where many environment and genetic-
related factors are involved.7 When tumour cells first appear, their regular supply of oxygen 
and nutrients is provided by the normal blood supply of the host organ, in which the tumour 
ascends. As the tumour expands, it is developed its own functional vascular supply by 
angiogenesis.27 However, the vasculature that is formed is primitive, chaotic and with a 
numerous structural and functional abnormalities.27,28 The tumour cells are not able to fulfil 
their increasing demand for oxygen and nutrients.9,28–30. As a consequence of the hypoxic 
medium31, the tumour cells tends to be more acidotic,9,27 a feature that make the cells more 
susceptible to thermal damage.31 
The development of the tumour cells mostly happens in localized tissue, but can spread to 
distant sites within the body by a metastatic growth. In this case, the tumour is referred as 
“malignant” and is usually associated with a poor prognosis for the patient,7,9 
Although the tumour cells are more vulnerable to temperature, the hostile microenvironment 
where the tumour cells developed make them to exhibit resistance to therapies as radiation 
or even certain types of chemotherapies.27,31 
 
1.2.2. Nanotechnology 
 
Nanotechnology is the understanding and control of matter at nanometric dimensions.10,32,33 
When reducing all three dimensions of a particle of a certain composition to the nanoscale, 
zero dimensional nanoparticles (NPs)34 and obtained and the original properties are usually 
modified. As a consequence of the dimensionality (1-100 nm),7,13,35 they are characterized 
by high surface area,7,35 which potentiates the interaction with surrounding molecules31 and 
size in the range of biomolecule entities. NPs can be very attractive for biomedical 
applications.35 They may be specifically targeted toward cancer cells, offering a major 
advantage over other therapeutic agents.7  
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The behaviours in nanoscale are not necessarily predicted from those observed in 
macroscopic scale. News phenomena may be observed,10,35,36 because properties such as 
melting point, fluorescence, electrical conductivity, magnetic permeability, and chemical 
reactivity change as a function of the size. More, the nanoscale materials have larger surface 
areas than similar masses of larger-scale materials, which allows a greater amount of the 
material that can interact with surrounding materials, thus affecting reactivity.37 
 
1.2.3. Magnetic materials 
 
Magnetic materials can be classified in one of five types of magnetism: ferromagnetic, 
diamagnetic, paramagnetic, antiferromagnetic and ferrimagnetic38,39 (Figure 1.1). The type 
of magnetism is dependent on the magnetic moments response to the application of an 
external applied magnetic field.38 Ferromagnetic materials display electron spins aligned 
parallel to each other at absolute zero. When the Curie temperature (Tc) is reached, the 
ferromagnetism disappears and the material turns paramagnetic. Under cooling, the 
ferromagnetic domains reform and the materials become ferromagnetic again. An 
antiferromagnetic behaviour corresponds to the antiparallel alignment of equal moments. If 
the antiparallel moments have different magnitudes, the materials are called ferrimagnetic. 
 
 
Figure 1.1 Scheme of the dipole alignment in zero applied field at room temperature for: (a) ferromagnetic, 
antiferromagnetic and ferrimagnetic materials. 
 
1.2.3.1 The M-H curve 
The magnetization (M) and demagnetization of a material under the applied magnetic field 
(H) is represented as a curve designed the M-H curve.40–43 The characteristic shape of a M-
H curve is sigmoidal and depends of the temperature and the magnetic field41. For high 
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values of H, the magnetization (M) approach to the saturation value (Ms) and will not 
increase no matter how strong H could be,41,44 because in that condition- the saturation, all 
domains are aligned.45 But not all the magnetic domains return to their original orientation 
when the applied magnetic field is reduced after reaching the Ms. Thus, when H returns to 
zero, there is a residual magnetization named remanent magnetization (Mr) which can be 
removed by applying a reverse magnetic field, called coercive field, Hc.43,45 So, open 
hysteresis represents an irreversible process of magnetization which is related with both 
intrinsic (e.g., particle size, shape, and magnetocrystalline anisotropy) and structural 
characteristics (e.g., grain boundaries, impurities, and vacancies) of the magnetic 
material.43,44 Typically, big particles (at micrometer range) lead to large hysteresis loops, 
while small particles lead to narrow hysteresis loops.41 A single 
magnetization/demagnetization cycle (a→b→c) produces a thermal energy proportional to 
the shaded area within the hysteresis loop46 (Figure 1.2). 
 
 
Figure 1.2 Typical hysteresis loop observed during magnetization/demagnetization of magnetic nanoparticles. 
M and H are magnetic flux density and magnetic field strength, respectively. A single 
magnetization/demagnetization cycle (a→b→c) produces a thermal energy proportional to the shaded area 
within the hysteresis loop.46 
 
1.2.3.2 Magnetism at nanoscale 
In bulk materials, the magnetic moments are divided in multiple domains (Figure 1.3a). As 
the particle size decreases, the domains sizes also reduce. Below a certain particle size value 
(denoted as critical size), the magnetic moments become organized in mono-domains 
a 
c 
b 
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(Figure 1.3a). These mono-domains haves a more favourable energetic configuration,6 
displaying different magnetic behaviours according to temperature. Below the blocking 
temperature, the superparamagnetic (SPM) NPs behave as a ferromagnetic, showing a 
typical hysteresis loop with net magnetization (black line in Figure 1.3b). For temperatures 
above the blocking temperature, the remanent magnetization becomes equal to zero as well 
as the coercive field (blue line in Figure 2.3b).10,13,46 The characteristic M-H curve of SPM 
NPs at room temperature is an overlap curve of curves with sigmoidal curve. When a 
magnetic field is applied to the SPM NPs, the magnetic moments tend to be oriented in the 
direction of the field, which from a certain value, leads all magnetic moments to be aligned 
parallel to their direction, reaching Ms. As the field is reduced, there is no Mr, and therefore 
no hysteresis loop47,48 as show in Figure 1.3b. 
 
 
Figure 1.3 a) Multidomains and monodomains representation under application and absence of a magnetic 
field. (b) Magnetization curves as function of the magnetic field for superparamagnetic particles under 
temperatures below de blocking temperature – ferromagnetic behaviour (black line) showing hysteresis loop; 
and above the blocking temperature - superparamagnetic behaviour (blue line) with no remanent magnetization 
(Mr) and no coercive field (HC). 
 
The conversion of AMF energy to heat through SPM NPs are explained essentially by two 
theories: Néel relaxation and Brownian relaxation9,31 (Figure 1.4). The first one causes 
energy to be released when the magnetic dipole of a particle flips between two stable 
orientations within a magnetic field that are separated by an energy barrier.31,46,49 This 
physical hindrance is directly proportional to size of the particles.49 The Brownian losses is 
due to random collision with other particles and the medium (like extracellular or complex 
components inside the cells that tends to counter the physical rotation of the suspended 
MNPs) and physical rotation of particles within an AMF.5,9,10,31,46 In a SPM NPs the 
Brownian fluctuations are sufficiently intense to randomly orient the individual magnetic 
b) a) 
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moments of each particle, leading to a zero global magnetization.50 The Brownian loss is not 
directly related to the magnetism of the SPM MNPs, but can increasingly modulate it as the 
particle diameter increases within the SPM range.5 
 
 
Figure 1.4 Néel rotation vs. Brownian rotation. (A) Néel rotation: the magnetic moment (arrow) rotates while 
the particle remains fixed (inner circle). (B) Brownian rotation: the magnetic moment (arrow) remains fixed 
with respect to the crystalline axes (lines inside the circle) while the particle rotates.51 
 
1.2.4. Hyperthermia  
 
The concept that heat can be used for therapeutic purposes has been described in the medical 
literature for centuries.31 The increase of the temperature above normal physiological 
temperature (ca. 37 ºC in humans) to a mild temperature, which does not cause cell death by 
itself, may have therapeutic effects and be defined as hyperthermia.28,31,52 Hyperthermia 
(HT) usually applies temperatures in the range of 41 to 50 ºC to induce apoptosis. Above 50 
ºC is considered thermoablation.52 Thermoablation leads to the necrosis of cancer cells, but 
may also affect healthy cells and therefore it is not desirable. 
The success of this approach is based on the differences between healthy cells and cancer 
cells,29 namely in the difference how the healthy and cancer cells behave when the 
temperature is increased.52 Cells in the mitosis are sensitive to heat probably because of the 
injury to the mitotic apparatus.28,52 As cancer cells have a faster cell division to quickly 
multiply,10,53 making them more sensitive to the increase of temperature. The physiological 
differences between normal and tumour tissue in the architecture of the vasculature (quite 
disorganized compared to the normal tissue)28,52,54 and with a low vessel density result in 
high susceptibility to the heat. In normal body temperature, the cancer cells take advantage 
comparatively to normal cell as the blood flow in them is faster. When the temperature 
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increase, the opposite happens: the blood flow in normal tissue increases whereas in the 
cancer tissue decreased. This happens because the cancer tissue cannot dissipate effectively 
the heat, remaining heated for longer time than the normal tissue. This, make the cancer cells 
to undergo into apoptosis phenomena, whereas normal tissue manages the high temperatures 
easily due to the increased blood flow.28 All these aspects make cancer cells more susceptible 
to heat.28,31 However, the specific mechanism of cell killing by hyperthermia is still 
unclear.28  
The duration, homogeneity of the temperature in tissue, tissue type and context of treatment 
influence the effects of HT in tumour cells.31,55 Depending on the thermal stimulation, there 
is a growing amount of experimental evidence showing that 43°C is the breaking point to 
develop cancer cell death.32,53 
A variety of techniques have been employed to achieve HT in the modern clinic practice 
including electromagnetic radiation, laser, microwave, radiofrequency and high-intensity 
focused ultrasound.31,43,56  
Depending on the extent of the body’s exposure to heat, there are three types of HT: whole 
body, regional and local5,31,42 HT. Whole body HT is achieved using water blankets and 
thermal chambers, whereas regional HT includes the perfusion of a tumour-bearing limb 
with part of the patient’s blood which is taken out and warmed ex vivo.5,31 Note, that these 
methods are not specifics and are technically challenging to perform repeatedly with 
reproducible heating levels. The last type of HT, the local HT, is more specific,31 and refers 
to heating only one body area, usually where the tumour is located.55,56 
 
1.2.4.1 Advantages and disadvantages of hyperthermia 
HT is independent of the cell cycle and this is a great advantage comparing to 
chemotherapies, which is cytotoxic to the cells, especially in specific phases of the cell cycle. 
Furthermore, HT can be used to treat cancer cells localized in many places like brain, thyroid, 
lungs, breast, prostate, hepatocellular carcinoma among others.53,56 Also, HT activates 
immunological responses to tumours for eradication by the host immune response.31 
Many clinical trials have documented that mild temperature HT can be safely administered 
to patients showing clinical benefits in terms of improved local control, palliation of 
symptoms and even overall survival. However, it is underutilized for a variety of reasons as 
the invasive methods of generating HT, the difficulty in maintaining temperatures at desires 
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levels, the lack of monitoring and modelling of HT. For example, in local HT, more 
specifically, luminal and interstitial HT, employ customized probes and applicators placed 
close to the tumour individually; it can apply a grid to achieve relatively uniform heating of 
the tumour; or metal antennas that are activated by an external energy source. However the 
placement of external heating sources usually invasive, challenging to the deep-seated 
tumour, and sometimes results in a nonuniform heat distribution.31 The external heating 
techniques such ultrasound and electromagnetic phase arrays are not invasive like the 
luminal and interstitial implants but the reproducibility and uniformity heating levels are 
challenging.3 
HT treatment is seen a great promise for cancer therapy, however the methods of reaching, 
maintaining, monitoring and modelling heating are still requiring a huge improvement.3 
 
1.2.5. Magnetic Hyperthermia 
 
Magnetic Hyperthermia (MHT) consists in applying an AMF in a magnetic fluid to produce 
heating through transformation of magnetic energy in thermal energy, raising the 
temperature in near the cancer cells.12,15,57–60 Magnetic fluids are class of magnetic materials 
constituted of colloidal suspension of MNPs.42,61 The first application of ferrofluids for 
hyperthermia treatment was investigated in the work of Chan et al.59 in 1993.  
The MNPs can be used in a specific areas of a human body by a simple direct injection to 
target tissue14,42 or by tumour specific antibody targeting42, followed by exposing to an 
external magnetic field.12,36,57,62 
As mentioned before, in the location of the malignant tumour, the proliferating cells require 
extra supplying oxygen and nutrients. Thus, small molecules (e.g., nanoparticles) can 
circumvent the aberrant endothelial barrier and leave the circulation to concentrate at the site 
of neoplasia. When a high concentration is reached locally, an alternating magnetic field can 
be used to target the tumour to raise the temperature of the medium.5,9,63  
The capacity of a material to generate heat under the influence of an AMF is characterized 
by its specific absorption rate (SAR)31,52 or specific loss power (SLP), expressed in Wg-1 
(1.1): 
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SAR =  SLP =  
∆T
∆t
C
m𝐹𝑒
                                      
 
where c is the heat capacity of the ﬂuid per unit mass, mFe is the concentration of the colloidal 
solution studied (g l-1 of iron) and ΔT/Δt is the measured temperature increase with time.52 
High values for SAR offers the advantages of enable the reduction of MNPs dose, and 
decrease the values of magnetic field strength and frequency that are required for MHT 
therapy.  
The SAR measurement is widely used to characterize the heat generation capability of the 
system,10 and it is a crucial parameter to modulate the tissue temperature that will be 
achieved during hyperthermia treatments. Overheating the tumour may result in serious 
damage to the surrounding healthy cells or in uncontrolled necrosis. On the contrary, the 
desired therapeutic effect cannot be achieved if the temperature rise is not high enough.5 
Although this measure cannot be directly compared between different experimental setup’s 
once the SAR value depends on the magnetization - strength and frequency of the used 
magnetic field5,52 and on the chemical, physical and magnetic properties of the material. 
Moreover, it also dependent on the dispersion media and agglomeration degree.5 The 
efficiency of power dissipated from SPM particles is enhanced when the particles’ size 
distribution is narrow.49   
Various factors influence the MHT, the extent of the heating produced and the time during 
which is maintained the heat as: magnitude of the AMF (the frequency and amplitude); 31,33,42 
the size; size distribution and other characteristic of the MNPs,5,31,40,42,46 the concentration 
of them in the target place as well the depth of the tumour within the body31 and the viscosity 
of surrounding medium.33,42 
 
1.2.5.1 Advantages of magnetic hyperthermia treatment 
Magnetic hyperthermia (MHT) have a great potential as a stand-alone treatment or adjacent 
therapy for cancer.39,52 The first successful clinical trial of interstitial hyperthermia in the 
treatment of human cancer using magnetic nanoparticles was attempted by Johannsen et.al54 
in 2005. Recently, favourable results of the ‘nanothermotherapy’ study in Phase II clinical 
trials run by MagForce Nanotechnology (Hospital Charité, Berlin) on patients suffering from 
(1.1) 
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glioblastoma multiform, show an improvement on patient survival from 6.2 to 13.4 
months.52   
The use of SPM NPs prevents the agglomeration of particles in the body, avoiding 
obstruction of blood vessels.47 Furthermore, these particles can reside in the body for long 
time, allowing several heat treatment of the tumour without re-introduction of the MNPs.15,30 
In addition, as SPM NPs tend to be less than 20 nm and resonate with a magnetic fields 
ranging from 10 KHz-10 MHz, they can easily penetrate soft tissues and bones.31 Besides 
the easiness in penetrating the cells, small particles (< 20 nm) are also more suited for in 
vivo applications.12 
MHT is advantageous in treating tumours in organs like lungs, which are easy to locate and 
avoid thermal bystander effect on nearby regions like heart.15 Moreover, MHT reaches 
deeper tissue than any other activation technology (light or acoustic waves).34 Direct 
injection to the target tissue allow to put in the target place sufficiently quantities of MNPs 
to generate the heat needed.31 MHT cal also be used in conjunction with other treatment 
modalities of the cancer, such as traditional radiotherapies, like chemotherapy or even 
surgery, for the purpose of improving the effectiveness of antineoplastic drugs.36 
The magnetic fluids have a specifically high absorption rate per mass but the normal tissues 
have a lower absorption rate, so it is possible to selectively excite areas containing fluids 
without interference with different neighbouring tissues. Such magnetic-field-induced 
excitation produces heat absorbed mostly by magnetic fluids and thus increasing the 
temperature only in regions with accumulated magnetic nanoparticles.14 
MHT has fewer side effects than chemotherapy or radiotherapy14,64 or anticancer drugs that 
have to be administered systemically, and with the lack of specificity towards a pathological 
site, requires a high dose to reach the local in the needed concentration. Moreover, the cancer 
cells develop resistance to the therapeutic effects of drugs.15,42 Conventional thermotherapies 
as photothermal, radiofrequency, infrared or ultrasound exhibit insufficient temperature 
elevation and non-homogeneity within the tumour15,42,49 and provides a minimally invasive 
way to deliver a therapeutic dose of heat specifically to cancerous regions.49  
 
1.2.5.2 Disadvantages of magnetic hyperthermia treatment 
The inability to precisely control the thermal dose and the dependence of heating efficiency 
on thermal dose rate is one of the limitations. It is know that large doses of heating can be 
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achieved by applying large fields amplitudes in a short time frame and result in a more 
sustained rise in temperature before heat is dissipated,31 which can provoke discomfort.15 
Non-uniform distribution of nanoparticles throughout the tumour generates cold spots in the 
regions where no or less MNPs are accumulated, and tumour cells remain untreated in those 
regions and regrowth occurs subsequently.15,31 Yet, these cold spots eventually get heated 
up by active thermal bystander effect. This effect can also heat up normal surrounding cells 
which need to be avoided; so 3D temperature measurement within the tumour region can 
help to avoid that situations.15  
When MNPs are injected intravenously, their biodistribution and achievable temperature is 
highly dependent on the formulation used, amount of MNPs injected, the target organ and 
the time point of addition.15,31 So, the desired heat in the local is complicate to achieved by 
intravenous administration.31 In addition, the interaction of MNPs with cells is complex and 
depending on the physicochemical conditions or the time of exposure, it may also result in 
the triggering of cytotoxic processes or the internalization of MNPs.35 Thus, the introduction 
of the MNPs relied on intratumourally injection, but it is invasive and is not synonymous 
with uniformity in the introduction of MNPs in the desired place.31 The optimization process 
is not yet well understood, experimental results from MNPs systems vary expressively.52 
The hydrophobic surfaces and the large surface area relative to volume48,53,58 and therefore 
possesses high surface energie,58 MNPs in vivo tend to agglomerate and to be released 
rapidly by the circulation.17,58,59 Moreover, they tend to have high chemical activity, and are 
easily oxidized in air (especially magnetite), generally resulting in loss of magnetism and 
dispersibility.58 To avoid these difficulties, the surface of the NPs must be modified by a 
biocompatible polymer.60,65  
 
1.2.6. Magnetic nanoparticles in the treatment of cancer 
 
In Table 1.1 are presented some of the nanoparticles used against cancer cells with different 
types of magnetism. 
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Table 1.1 -Some examples of different types of NPs used against cancer cells.39 
 Ferrimagnetic Paramagnetic Diamagnetic Antiferromagnetic 
 iron oxide palladium zinc oxide cobalt oxide 
 nickel zinc ferrite cerium oxide biosynthesized silver - 
 magnesium ferrite titanium dioxide gold - 
 - platinium copper - 
 - neodymium oxide selenium - 
 
 
For biomedical applications, MNPs should fulfil a variety of requirements as: (i) SPM 
behaviour at room temperature, in order to avoid particle aggregation12,40,45,57 (and escape to 
induce dangerous thrombosis of blood vessels);34 (ii) large Ms, so as to show a large response 
under the application of a magnetic field40,45,66 and low coercivity (Hc)49 (iii) limited particle 
size (<20 nm)40,66 to escape the phagocytosis of reticuloendothelial system and penetrate into 
capillary vessels in body tissues, which ensures an effective distribution in specific tissues;17 
(iv) high size unirformity;45,49 (v) biocompatibility40,57,65- nanoparticles are usually coated 
with either biological or biocompatible molecules;55 (vii) the carrier particles must have a 
long retention time while circulating in the blood40,53 - preventing agglomeration and 
minimizing adsorption of plasma proteins that enhances phagocytosis (opsonins) on the 
MNPs by covering them with a thin layer of biodegradable polymer.40 
 
1.2.6.1 Why Fe3O4? 
Fe3O4 or γ-Fe2O3 (magnetite and maghemite respectively) are the MNPs most used in the 
research groups and it becomes evident why are attractive candidates for use in human body.  
Fe3O4 is a ferrimagnetic compound with two different cation sites in a unit cell: 8 tetrahedral 
A sites, and 16 octahedral B sites. Magnetite is an inverse spinel, which means, 
(Fe+3)[Fe+2Fe+3]O4, where the specie in curved parentheses stand for the tetrahedral sites and 
the square parentheses stand for the octahedral sites.67 
The iron oxide nanoparticles have good biocompatibility, non-toxicity,9,28,31,52 potential to 
exhibit superparamagnetic properties if the particle sized is below 20 nm,9,28,31 the specific 
surface is high, biodegradability,52 high chemical stability28,31,68 and are excellent conductor 
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of heating, transmitting it to the adjacent tissues.31 In addition, the heating efficiency in 
aqueous colloids of these materials is well established.69 
Iron is essential in the human body! Besides, it exists in several body entities as in the 
haemoglobin, which is essential for human survival, it have great stability and unique 
magnetic properties. Furthermore, iron oxides are not only biocompatible as they can show 
therapeutic effect, where others nanoparticles as FeSi or FePt fail. Besides, US FDA approve 
the use of the ultrasmall and/or SPM NPs of iron oxide for MRI (Magnetic resonance 
imaging)9,17. However, it is important to refer the fact that several agents have been removed 
from the market in the late 1990s and 2000s because the possible side effects. The toxicity 
is not always immediately detectable.9  
The surface of the iron oxide MNPs has iron atoms on the surface that can coordinate with 
molecules or get protonated/deprotonated. This capability allows to modifying the surface 
pre-and post-synthesis with many functional groups whether inorganic and organic as 
monomeric ligands (dopamine, phosphoric acid), multimeric ligand and zwitterionic 
ligand31,70; and therefore improve their stability and increase their circulatory halt-time as 
preventing aggregation, improving their hydrophilic properties and lower the possible 
cytotoxicity4,31,70. The possibility of an easy functionalization10,33,53 allow obtain a 
multimode MNP with potential application in several areas.53  
1.2.6.2 Toxicity 
The long terms effects of the MNPs still one the major concerns in their use because of the 
lack of knowledge of the effect of accumulation of particles in body.9,71 For example, in 
blood transfusion, patients suffering for sickle cell anaemia require the constant 
administration of iron chelating agents in order to control the excess of Fe. Generally, these 
patients, have reduced life expectancy due to their condition but also due to the iron 
overload.9 Landeghem reported in their study that MNPs of iron coated with aminosilanes 
applied in gliobastoma on phase II were localized in macrophages in areas of tumour necrosis 
rather than the cancer cells themselves.72 
Spherical NPs with zwitterionic charged surfaces and hydrodynamic diameter of about 5 nm 
are released by the kidneys and not entrapped within the reticuloendothelial system (RES) 
while larger particles (20 nm) are captured by reticuloendothelial macrophages.31 
Another question, is the time that the iron MNPs can persevere in the body, because they 
can be uptake by phagocytes cells but also by nonphagocytic cells. For example, the 
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endothelial cells surrounding the blood vessels, are a sub-group of the latter, and they can 
engulf the MNPs of iron. Due to oxidative stress, in the case of the γ - Fe2O3 uptake, the cells 
do not survive frequently more than 24 hours post micropinocytosis, and MNPs are cleared 
through urine rapidly. However, some organs as the lung, liver or kidney have been 
identified as the main target organs of bioaccumulation of the MNPs in some studies68,69,71 
as well as the macrophages in systemic circulation.68 
The possibility of these particles to escape from physiological barriers and contact vital 
organs as the brains is also of high concern.9  
Nowadays some studies report toxicity to healthy skin and lung tissues in vitro tests.9 
However others studies report iron oxide as innocuous to normal rat hepatocytes and human 
fetal lung cells (IMR-90).39 These inconsistent results may be due to factors such as dose 
and exposure duration;39,68 and MNPs properties and characteristics such as shape, size, 
charge, biodistribution,  functionalizations39,57,66,69,71 or life cycle69,71 which influence the 
results. Further, the behaviour of the MNPs in biological media - the interactions with the 
cells and tissues can alter the physicochemical properties and contribute in the discrepancy 
of results of in vitro and in vivo.57,69 With a large variety of MNPs and possible behaviours, 
it is difficult to draw general conclusions about their possible toxicity.71  
As the possibility of toxic effects are not clear, coating is one of the protective measures to 
be implemented to minimize iatrogenic complications and damage of healthy tissue.9 An 
appropriate coating diminishes systemic toxicity while improving specificity to cancerous 
cells. However, complete safety is never guaranteed.9 Also, the MNPs should be tested for 
microbial contaminations (bacteria, yeast, and mold) eliminating other parameter, which 
could lead to ambiguous cytotoxic results. The majority of MNPs of iron can be considered 
sterile due to the synthesis procedures; however, contamination can be introduced in various 
downstream processes such as surface functionalization.57 
The consensus at this moment is in favour of their use in vitro and in vivo experiments 
involving animals. 
 
1.2.7. Synthesis and coating of MNPs 
 
Various methods of synthesis of magnetic nanoparticles are described in literature.18 The 
approaches may be chemical,5,42,73 biological42,73 or physical.5,42 The chemical methods are 
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the simplest and the most efficient, having a sensible control of composition, shape and size74 
whereas the biological route do not produce homogeneous particles.74 The physical 
procedures can be used to produce high purity nanomaterials, but the geometry of the 
synthesized particles is difficult to control.45,74 Both methods are able to prepare magnetite 
with controllable particle diameters, however, well-dispersed aqueous Fe3O4 nanoparticles 
are difficult to achieve.18 In table 1.2, it is presented some possible methods to synthetize 
iron MNPs. 
The synthesis method has an important role in the magnetic properties62 as it the 
size,33,35,45,62,75 size distribution,35,62 shape,45,75 particle surface characteristics,29,53,62,75 
crystalline lattice, oxidation state of iron ions,53, etc..42,45,59,62,74. Various shapes of iron 
oxides particles such as spheres, cubes, worms, stars, rods, octahedrons, and prism59 are 
described in literature.  
This work is focus on the use of chemical precipitation to prepare the iron MNPs. 
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Table 1.2 -Summary of some synthetic methods of magnetic nanoparticles.  
Methods  Ref. 
Chemical 
co-precipitation 5,18,35,53,73 
thermal decomposition 5,18,29,35,53 
microemulsion 18,29,35,53 
hydrothermal synthesis 5,53,76 
microwave assisted synthesis 73 
solvothermal method 45,73 
self-assembly 60 
combustion synthesis 73 
sol–gel 73 
polyol method 5 
Physical 
Gas phase deposition, 5,50 
ball milling 5,50 
laser-induced pyrolysis 5,45,50 
electrodeposition 45 
pulsed laser ablation 45,50 
aerosol 45,50 
Biological 
magnetotactic bacteria 73 
mediated by proteins 50,53 
mediated by fungus 50 
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1.2.7.1 Chemical Precipitation 
Co-precipitation of ferrous and ferric salts in aqueous solution represents a straightforward, 
facile and efficient synthesis strategy to synthetize iron oxide NPs on a large scale.70 A wide 
variety of experimental parameters, such as: i) pH; ii) ionic strength; iii) concentrations ratios 
of Fe2+/Fe3+; type of precipitation agent; v) strength of the basic agent;5,45,70 vi) reaction 
temperature;5,18,45,53,70 and vii) stirring rate5,18,45,47,53 were described in the literature that 
influence size, shape, magnetic and surface properties of the MNP synthetized. For example, 
if the concentration of the salts is enlarged, there is an increase in the number of particles, 
with a subsequent loss of uniformity in size.5,45,53 However, the control of the particle size 
distribution, crystallinity and oxidation is limited once the reactions are thermodynamically 
driven.13,47,70 This could be overcome by others alternatives as thermal decomposition. 
However, the MNPs synthetized by this method generally are non-aqueous, being soluble 
only in organic solvents. Post-preparative ligand-exchange procedures are require to turn the 
particle water-soluble and biocompatible.70 
The precursors used are ferric (Fe3+) and ferrous (Fe2+) chlorides, sulphates, perchlorates or 
nitrates, etc..5,45,76 They are, first dissolved in an acidic aqueous solution to prevent the 
individual precipitation of hydroxides whose solubility products are very high. Then they 
are “co-precipitated” (meaning the two valences of iron ions together) under the addition of 
a strong base (commonly NaOH), according to the reaction 1.2.5,13,45,53 It is not needed high 
temperatures18,76 and the resulting particles surface possesses hydrophilic properties. Also, 
it can produce fine, high-purity, stoichiometric particles of single and multicomponent metal 
oxides.35  
 
2 Fe3+ +  Fe2+ + 8 OH- → Fe3O4 + 4 H2O 
 
Controlling the reaction atmosphere is also of crucial importance in this method, since -
magnetite (Fe3O4) easily oxides into maghemite (-Fe2O3), a ferrimagnetic iron oxide phase 
or hematite (-Fe2O3), a antiferromagnetic iron oxide. Therefore, inert conditions are 
required to obtain magnetite, or a controlled oxygen atmosphere.5,45,53 For example, bubbling 
the solution with an inert gas does not only protect the critical oxidation of magnetite, but 
also reduces particle size when compared with methods that do not remove oxygen. 
( 1.2) 
 
(3. 
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1.2.7.2 Geometry and Size 
The geometry and size of the MNPs are important to define their lasting time in the 
bloodstream. Rapid removal of them from circulation systems by opsonins or white cells can 
substantially reduce their biomedical functionality. The dimensions of the MNPs directly 
influence their trajectory in the body. MNPs larger than 100 nm are usually opsonized63 and 
if lower than 5-6 mm diameter are removed by renal filtration.77 In general, the larger the 
particle, the lower their spent time in blood circulation. Thus, it is commonly accepted that 
MNPs with a diameter of  between 1 and 100 nm are the most suitable for in vivo 
application.63 
Spherical MNPs have been the most studied form. They are isotropic whereas the elongated 
MNPs, exhibit magnetic shape anisotropy. The magnetic shape anisotropy is a property that 
reflects the existence of a preferential direction magnetization dependent of the particle 
shape, being an advantage.63 The magnetic moments of spherical nanoparticles are arranged 
in a random way, and tend to cancel, diminishing the strength of the magnetic signal. In 
anisotropic MNPs, the magnetic moments tend to orient themselves according to their long 
axis and they will always be pointed to two possible ways, in the same direction. Thus, the 
strength of the magnetic signal is enhanced, i.e., elongated particles experience a greater 
strength when compared to spherical particles of the same volume.63  
 
1.2.7.3 Surface modification of iron oxide MNPs 
As MNPs usually tend to aggregate,15,33,35,45 the coating of synthesized MNPs is advised.33,45 
Furthermore, the naked MNPs can stimulate ROS generation and non-specific interactions 
with opsonins5,10,33,53 (albumin, immunoglobulin (IgG), apolipoproteins, etc.), which adsorb 
onto the MNP surface, thereby completely obstructing their functionality and allowing their 
uptake by the phagocytes of the immune system (IS)5,33,53 which results in increased 
cytotoxicity.45 
As the microenvironment where the cancer cells are developed are hostiles (acid medium, 
low oxygen) the surface modifications must take that in account.45,53 For example, if the 
intend is reduce the adsorption of MNPs by the opsonins, they may be coating with 
amphiphilic molecules and then increase the time in blood circulation.33  
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The interaction between the coating agent and the MNPs is critical35,45 and  the special 
attention must be taken to insure the stability of the MNPs. For example, physically adsorbed 
coatings (by electrostatic interactions or hydrogen binding) show limited stability in 
comparison to chemically adsorbed coatings agents. The steadiness of the coating also 
depends on the quantity of the chemical interaction that each molecule or macromolecule 
can establish with the MNPs surface.13 
The goal stands by offering a non-toxic35,48 and biocompatible coating5,35,45,47,62 so that the 
crystalline character of the oxide is retained33,53,62 as well increase the chemical stability of 
the Fe3O4 NPs
5,10,17,18,35,44,45,48,53 in vivo. Further, the route employed should be simplistic 
and effortlessly.62   
A variety of materials have been reported to coating the Fe3O4 MNPs. Some are presented 
in table 2.3.  
In this work, it was tried to synthesize magnetic NPs of iron oxide, coated with 
biocompatible and non-toxic chitosan biopolymer.  
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Table 1.3 - Some materials reported as coating/crosslinkers and linkers to the iron oxide (Fe3O4). 
Coating Examples Ref. Examples Ref. Examples Ref 
Organic 
molecules 
oleic acid 17,35,78,79 castor oil 30 oleylamine 80 
phosphates 54 nitrilotriacetic acid 81 dimercaptosuccinic acid 71 
Gallic acid 75 gluconic acid 82 Carbon 83 
Caffeic acid 84,85 lactobionic acid 82 RHGD cyclic peptide 86 
dopamine 81,87 polyacrylic acid 82 hyaluronic acid 88 
dopamine 
sulfonate 
89 folic acid 15,47,90,91 HEMAGl 92 
citric acid 93,94 iminodiacetic acid 16 sodium hyaluronate 87 
acid carboxyl 95     
Polymers 
Dextran 15 gelatin 65 methacrylamide 92 
Starch 96 chitosan 12,16,18,30,40,44,48,65,73,96–102 fucan polysaccharides 103 
Alginate 104 o-carboxymethyl 
chitosan 
14 
chitosan-L-glutamic 
acid 
41 
pullulan 105 
aminosilane 106,107 polystyrene 78 Pluronic® block 
copolymer 
108 
PEG 71,88,109–111 PNIPA 12 
Inorganic 
Materials 
Au 112 alkosilanes 78,113–1151 silica 44 
Ag 117 silicone 118 Si 119 
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1.2.7.4 Chitosan 
Chitosan is a biopolymer with a unique chemical structure, high density, free amino and 
hydroxyl groups120 and easy application.62 Amongst the biocompatible natural materials 
employed as coatings, chitosan has been used due to its known properties as: 
biocompatibility, biodegradability,17,40,44,120–122 bioactivity,18,29,122 hydrophilicity (provides a 
barrier to adsorption of protein, reducing the macrophage),30,44,123 bioadhesion,17,73 low 
cytotoxicity,15,16,18,30,120 antioxidant, anti-inflammatory120 and antimicrobial properties.16,120 
Chitosan have been used for various biomedical applications  such  as  tissue  engineering,  
drug  delivery,15,65  cell  encapsulation, wound  healing  along  with  orthopaedic,  
periodontal, pharmaceutical  and  gene  therapy65 among others.   
Chitosan or poly[β-(1-4)-2-amino-2-deoxy-D-glucopyranose], is obtained by partial alkaline 
deacetylation of chitin15,29,120 (about >50%), a main component of the exoskeleton of  
crustacean,  mollusc  shells,  fungal  cell walls  and  insect  cuticles.18,65,120 Their structure is 
very similar to that of cellulose120,124 and is characterized by their molecular weight and 
degree of acetylation,120 which are determinant on various properties including solubility, 
biodegradability, toxicity, antimicrobial activity, etc.124 This biopolymer has a positive 
charge, being soluble in various acids.100 
In addition, the free amino groups and hydroxyl groups can be easily used for further 
functionalization17,33,40,44,73,121 and improve the colloidal stability in vivo in blood 
circulation.17,122 But chitosan cannot dissolve in a physiological environment (pH = 7.4), 
only in acidic solution (pH < 6),15,120 where the units of glucosamine (-NH2) can be converted 
into their protonated and soluble form (NH3
+).120,124  This is the main disadvantage of coating 
the MNPs with chitosan because can interact with anionic components (glycosaminoglycans 
and proteins).125 But, Nunes et al., demonstrated that chitosan can link to genipin and caffeic 
acid molecules, becoming less soluble in acid medium between chitosan chains.126 Based on 
this result, there is a way to make chitosan more stable in acidic medium. So, the main 
disadvantage of chitosan can be overcome. 
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1.3 Motivation 
 
As everything it is used inside of human body, biocompatibility is required. More, in the 
case of the MNPs, to achieve better results in the heat generated, disaggregation is need. So, 
coating is a possible method to achieve these two requirements, for the use of the MNPs in 
hyperthermia therapy. Promote a good link between the iron oxide and the coat is 
fundamental, so adversely effects are avoiding as well to achieve better heat production 
during the hyperthermia treatment. 
In the beginning of this work dopamine never was used to promote this type of bonding 
(between iron oxide and chitosan) in this type of therapeutic (magnetic hyperthermia). 
Tumour cells are more acid and chitosan have poor resistance to acid medium. To overcome 
this issue, crosslink with a known molecule is proposed: genipin. Due to structural similarity 
with dopamine, caffeic acid was proposed to see if could promote a good link between the 
iron oxide as well to see of the link to the coat is stronger than using dopamine and genipin. 
 
1.4 Objectives 
 
The general objective of this work was to prepare suitable magnetic nanoparticles to be used 
in magnetic hyperthermia.  
To reach the main purpose of this thesis, it was necessary accomplish minor objectives: 
 To produce magnetic nanoparticles (MNPs) of iron oxide, preferably magnetite 
superparamagnetic NPs; 
 To functionalize the produced nanoparticles through two different ways: one using 
dopamine (DOPA) and the other using caffeic acid (CA); 
 To coat the nanoparticles with chitosan; 
 To characterize structural and morphologically the NPs through different techniques 
as X-ray diffraction (DRX), Fourier transmission infrared spectroscopy (FTIR), 
transmission electronic microscopy (TEM), Zeta Potential and hydrodynamic 
diameter (DLS) and to evaluate the magnetic properties after the coat of chitosan by 
Superconducting Quantum Interference Device (SQUID); 
 To perform hyperthermia measurement of the produced MNPs. 
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Experimental Procedure 
 
This chapter describes, briefly, the materials and procedures used, as well as the 
characterization techniques. The reagents used were commercially available and used 
without pre-treatment. The main characteristics of all reagents used are in Annex A. To avoid 
the production of impurities was used Type 1 water from Millipore Simplicity UV Water 
Purification System. 
Figure 2.1 represent the main steps of this experimental work.  
 
 
 
Figure 2.1 Schematic representation of the main steps during laboratorial work. In top, the synthesis of 
Fe3O4 and down, the paths for the functionalization and coating. 
 
Fe3O4
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(under N2)
FeCl2∙4H2
O 
FeCl3
NH
4
OH 
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It is divided in four parts: i) synthesis of iron oxide MNPs; ii) functionalization and coating 
of the MNPs synthesized; iii) morphological, structural and magnetic characterization and 
iv) magnetic hyperthermia measurement (based on the release heat by the NPs). 
 
2.1 Synthesis of iron oxide MNPs 
 
The synthesis of the iron oxide MNPs was adapted from the chemical co-precipitation 
method described on reference (78). The experimental apparatus used in the synthesis is 
shown in Figure 2.2. The reagent quantities used in the synthesis of MNPs are presented in 
Table 2.1. 
 
 
Figure 2.2 Experimental apparatus used for synthesis of NPs of MNPs.  
 
Table 2.1 Reagent quantities used in the synthesis of MNPs. 
 FeCl2∙4H2O FeCl3 Fe3+/Fe2+ 
Mass (g) 7,2021 4,98 - 
Molar quantity (mol) 0,0444 0,0250 Ratio=1,76 
 
 
Briefly, the MNPs were produced by co-dissolving FeCl3 and FeCl2∙4H2O in 50 mL of water 
under nitrogen gas with vigorous stirring at 80ºC. Then, at this temperature, 25 mL of 
ammonium hydroxide were rapidly added into the solution. The solution immediately turned 
black. The solution was kept reacting at 80ºC for 30 minutes and cool down to room 
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temperature. To get particles free from sodium and chloride compounds, the MNPs were 
magnetically separated and washed with water. This procedure was repeated three times, and 
then MPNs were dispersed in 72 mL of water. The pH of the suspension of NPs was neutral. 
 
2.2 Procedures for coating of MNPs 
 
2.2.1 Functionalization of the MNPs with dopamine 
 
Dopamine was used as the anchor to present functional molecules on the surface of iron 
oxide magnetic nanoparticles. Adapting the procedure of (81), dopamine (38.00 mg) was 
dissolved in 14 mL of water and ethanol (2.5:1). The functionalization was made by mixing 
5 mL of iron oxide (dropwise) to dopamine solution under using an ultrasound bath for 
homogeneizing. After, the pH was adjusted to 4-5 (4.57) with HCl (1 M). The resulting black 
solution was put in the ultrasound for 20 min. The MNPs were magnetically separated and 
washed with hexane. This process was repeated three times. The MPNs functionalized with 
dopamine were dispersed in 22 mL of ethanol and denoted as F.DOPA. 
2.2.2 Addition of genipin molecule as “tethering” agent 
 
Genipin molecule was reacted with dopamine to act as bridging ligand to chitosan. 
The addition of genipin to the functionalized dopamine’s iron oxide was made in the 
proportion of 1:2. 30.1 mg of genipin, was dissolved in 20 mL of ethanol followed by 5 min 
in the ultrasound. 4.8 mL of F.DOPA suspension were diluted in 20 mL of water:ethanol 
(2:3). The functionalized iron oxide was dropped to the genipin solution under ultrasound 
and left reacting overnight in the dark. Afterward, the MNPs were centrifuged twice at 6000 
rpm during 90 min and then the pellet powders were ressuspended in isopropyl alcohol. 
Lastly, the MNPs were magnetically separated and suspended in 30 mL of ethanol, 
designated as F.DOPA.GP. 
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2.2.3 Functionalization of the MNPs with caffeic acid 
 
Adapting the procedure of functionalization with dopamine of reference 81, 36.10 mg of 
caffeic acid (CA) was dissolved in a mixture of water and ethanol on the molar ratio of l2.5:1. 
Then 5 mL of iron oxide was added dropwise to the CA solution under ultrasound. After, 
the pH was adjusted to 4-5 (4.46) with HCl (1 M) and then, the black solution was 
ultrasonicated for 20 min. Lastly, the NPs were separated magnetically and wash 3three 
times with ethanol, and redispersed in 40 mL of ethanol. These particles were designed FCA. 
2.2.4 Coating of the functionalized MNPs with chitosan 
 
A chitosan solution (CS) was prepared with the concentration of 1.5% (w/v) in 0.1 M acetic 
acid and was stirred over night at room temperature. After complete dissolution of chitosan, 
the solution was filtered in a glass fritted funnel (G1). 
Despite knowing that coating isolated MNPs is extremely hard as well as getting them 
homogeneously coated with similar coating thickness, it was that the starting point to 
determine the amount of chitosan to add to the samples. So, it was estimated the average 
particle diameter as well as total volume of the coating and multiplied by the total estimated 
number of particles present in the volume of solution to be coated. 
 
2.2.4.1 Coating of F.DOPA.GP with chitosan 
303 µL of 1.5% (w/v) chitosan solution that was diluted in 20 mL of water under ultrasound.  
4 mL of the F.DOPA.GP were dropwise to the chitosan solution under ultrasound. This step 
takes almost 40 min. The mixtures were left reacting in the dark at room temperature for 48 
h. After, the NPs were magnetically separated and washed three times with water and 
resuspended in 3 mL of water.  
In order to optimize the coating, the same amount of CS was added to a smaller amount of 
MNPs. Thus, 303 µL of CS was diluted in 20 mL of water under ultrasound and 1 mL of 
F.DOPA.GP was dropwise to the chitosan solution. The following steps are equal to those 
above. This was the solution that was characterized. 
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2.2.4.2 Coating of F.CA NPs with chitosan 
To caffeic acid nanoparticles with chitosan two paths were followed. The first one was based 
on the procedure reported in the reference (126) and the second was based on the reaction of 
the carboxylic acid group of the caffeic acid with the amino groups of chitosan using 
carbodiimide chemistry. 
2.2.4.3 Coating of F.CA with chitosan using ceric ammonium nitrate 
3.17 mL of CS was dissolved in 209 mL of water under ultrasound. Ceric ammonium nitrate 
CAN (0.1048 g) was dissolved in 3.17 mL of water. 2.72 mL of F.CA was added to the 
previous solution. Under nitrogen gas, FCA-CAN was added under ultrasound to the CS 
solution protected from light and left to react always under ultrasound during 3 hours. The 
orange solution was separated magnetically and ressuspended with water. The suspension 
was centrifuged six times for periods of 30 min at 6000 rpm.  Lastly the NPs were lefted in 
26 mL of water (Figure 2.3).  
 
             
Figure 2.3 Final aspect after coating the MNPs with chitosan via CAN. 
 
2.2.4.4 Coating of F.CA with chitosan via 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide  
FCA NPs were magnetically separated and ressuspended in the same volume with 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (pH 5.5) to avoid irreversible oxidation of 
catechol group of caffeic acid. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) 
was added to the FCA solution immersed in a ultrasound bath for homogeneization (in cold 
water) and stirred at room temperature overnight, at 25 rpm and at 360º in a PTR-35 360° 
vertical multi-function rotator from Thomas Scientific. The FCA solution was dropwise to 
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the CS solution (2 mL of the 1.5% m/v diluted in 15 mL of water and at pH≈2.5) under 
ultrasound and put again in the rotator to stirred for 24 h. After, the MNPs were magnetically 
separated twice and washed with water and ressuspended in 5 mL of water. The 
stoichiometric molar ratio of FCA and EDAC was 1:7.5. The MNPs was designated EDAC. 
 
2.3 Characterization of the NPs 
 
2.3.1 Structural and morphological characterization  
 
2.3.1.1 X-ray diffraction  
X-rays diffraction  (XRD) is a very useful technique aiding qualitative and quantitative 
analysis on the crystalline structure and particle size.127,128 X-ray techniques are generally 
non-destructive and allow information about the ensemble average of many particles in 
contrast to direct imaging techniques such as electron microscopy that only gives data 
concerning a small part of the sample. This data that may not be truly representative of the 
material.128 Exposing a sample to X-rays beam, some of those X-rays are diffracted 
according to a certain angle (2θ) matching characteristics crystallographic directions of the 
material as given by the “Bragg’s law”:  
 
nλ = 2dsinθ                                                        (Eq. 2.1) 
 
where λ is the wavelength of X-rays source, θ is the angle between the incident waves and 
the crystal surface, and d is the spacing between the crystallographic planes of the crystal.129 
The obtained MNPs were dried at 60 ºC overnight and left cool to room temperature in a 
desiccator before characterization by XRD. 
The analysis was performed in a diffractometer of powders Panalytical Empyrean, using 
Gonio as a scan axis, Cu radiation, λ=1.54056 Å, at 40 mA, 45 kV, with a range of 15º - 
100º and a step of 0.013º. Data acquisition was done automatically using the software 
Identification and Crystallite size calculator – high Score Plus from Panalytical, between 15 
and 99° (2θ). The peak identification was made using the data base from The International 
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Centre for Diffraction Data (ICDD), PDF 4+ (2015). The Rietveld refinement was made 
using a GOF of 1.509. 
 
2.3.1.2 Fourier transformed infrared spectroscopy 
The MNPs synthetized as some reagents were analysed by Fourier transformed infrared 
spectroscopy (FTIR) technique, in order to identify the characteristic vibration between 
atoms presents in the samples, helping to identify specially the organic functional groups of 
the coating species.  
The samples analysis was performed on a Mattson Instruments, GALAXY SERIES FT-IR 
7000, for an infrared region of 4000-350 cm-1, with a step resolution of 4 cm-1 and a 
background scan of 256. The sample was analysed in ATR mode. 
2.3.1.3 Thermogravimetric Analysis (TGA) 
TGA provides quantitative evidence of the thermal stability of the samples, allowing to 
determine the amount of organic content present on the MNPs. This is an tremendously 
valuable technique for surface characterization on MNPs and to understand the success of 
the coating reaction.17   
The weight variations with temperature were performance in a Setaram model Labsys™ TG-
DDSC16. This technique provides information about the transformation that is occurring by 
overlapping the weight loss curve as a function of temperature. The NPs of magnetite were 
dried at 60 ºC during 12 h and milled in a mortar before. The analyses were done by heating 
the powder from room temperature to 600 ºC at rate of 10 ºC/min under flowing air. 
2.3.1.4 Transmission Electron Microscopy (TEM) 
The morphology and size distribution of the MNPs before and after were studied by using 
transmission electron microscopy. A Hitachi® model H9000 with an acceleration voltage of 
300 Kv microscope was used for the analyses.. The sample were dispersed in ethanol and 
stirred in ultrasound for 30 minutes. The samples were prepared by dropping the suspensions 
on a copper grid coated with an amorphous carbon film.  
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2.3.1.5 Hydrodynamic Size (DLS) and Zeta Potential 
Hydrodynamic particle sizes were measured by Dynamic Light Scattering (DLS)130 that can 
provide information about the size and size distribution in suspensions in a short time.11 A 
cuvette containing the sample is irradiated by a polarized laser beam, which leads to a 
scattering signal in all directions, depending on the particle size. Once the particles are 
suspended within a liquid, undergo Brownian motion and these movements induces temporal 
variations of the scattered intensity recorded at a given angle. The larger the particle, the 
slower is the browninan motion. The time Auto-Correlation Function (ACF) of the intensity 
signal is analysed to obtain the Particle Size Distribution (PSD).130 DLS is very sensitive to 
the quality of dispersion, degree of aggregation of the NPs and stability of the suspensions, 
that can create misleading results.11 
The particle hydrodynamic size, as well as the Zeta Potential were measured by a Malvern 
Zetasizer Nano ZS™. For DLS measurements water was used as the dispersion medium at 
25ªC using plastic cells with a detection angle of scattered light at 173º. The samples were 
diluted to a concentration of 5.0x10-4 g/L and stirred for 5 minutes. 
The isoelectric point of pure and coated samples and additional information about the coating 
of nanoparticles were obtained using the measurements of electrophoretic mobility’s. 
The ζ-potential was measured by electrophoretic measurements in a 0.01 M KCL solution. 
To change the pH of the suspensions in DLS and ζ-potential measurements NaOH and HCl 
were used. 
 
2.3.2 Magnetic Characterization 
 
Superconductor Quantum Interference Device (SQUID) magnetometers was used to 
measure the magnetic properties of the sample iron oxide nanoparticles before and after 
coating. In a SQUID magnetometer, the samples moved through the external magnetic field. 
The magnetization measurements were performed as a function of temperature between 
10K and 390K under an applied magnetic field of 50 Oe. The ZFC (Zero Field Cooling) 
curves were obtained after cooling in Zero Field, from room temperature. The FC (Field 
Cooling) curves were obtained after cooling in the measurement field. The magnetization 
curves as a function of applied magnetic field were performed at 300 K varying the pitch 
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between -55 and +55 kOe. These measurements were performed in a Quantum Design- 
MPMS magnetometer from Centro de Física Matérica Condensada- Faculdade de Ciências 
from University of Lisbon.  
 
2.3.3 Magnetic hyperthermia measurements 
 
A more effective way to destroy cancer cells is to use the nanoparticles as little magnetically 
driven drill bits. Through a pair of Helmholtz coils arranged perpendicularly it is possible, 
in a simple way, to generate rotating magnetic fields that are few millitesla. However, it is 
necessary a system of cooling because increasing the magnetic field beyond this point can 
result in resistive heating due the continuous current131.  
The measurements were made in an equipment consisting by a power source (EASYHeat 
0224 FF CE, Ambrell), a Helmholtz coil with two twists, a cooling system (Chilly 25-S 
HYFRA) and an optical pyrometer FTP LN2 (sensor - FLUOTEMP Fiber Optical 
Temperature Sensor System). The determination of specific absorption rate (SAR) was 
based on the obtained results in measurements of heat release of the samples, when subjected 
to an external magnetic field of alternating current. 
The measurements were made in an Ambrell jar, where 3 mg of the test sample were 
dispersed in 3 mL of ethanol and, similarly, a sodium citrate solution (5%). To disperse the 
MNPs the samples were stirred for one hour in. The container was then placed inside the 
cork holder which was among the coils of the Helmholtz coil. The alternating current 
magnetic field was applied for 5 min using the following parameters: a current (I) 400 and 
the frequency (f) at 275 kHz. Under these conditions the maximum magnetic field applied 
alternating value will be ≈ 120 Oe. 
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Results and Discussion 
 
The main goal of this work was to synthesize magnetic nanoparticles (MNPs) with 
applicability in magnetic hyperthermia through introduction of news groups (the ligands 
agents). For the reasons given above, the chosen MNPs to synthetize was magnetite, due to 
their properties as biocompatibility, strong magnetization, low toxicity among others 
reported here and in a large bibliography over the last years. 
There are many ways to synthesize NPs of magnetite. The methods pass by thermal 
decomposition, chemical co-precipitation, hydrothermal technique, electrochemical 
synthesis, ultrasound132 among other already mentioned in this work. But, the chemical 
precipitation is the most widely used synthesis procedure, both for laboratory scale and for 
industrial use.133 The reasons for the popularity of the chemical precipitation are the low 
temperature of reaction;  the easiness and low cost,100,133,134 conjugated with the harmless 
and biocompatible reagents, which make the resultant MNPs suitable for biomedical 
applications once produces NPs in aqueous phase with a no impurities.100,133  
 
3.1. Synthesis of iron oxide MNPs 
 
Alkaline chemical precipitation was used to synthesize iron oxide MNPs. The chemical 
reaction of this synthesis is present in reaction 1 of the Table 3.1. To provide a complete 
precipitation of the used iron salts and avoid oxidation of magnetite, a high pH was 
required,105,135 as well as N2 atmosphere. Bubbling nitrogen gas through the solution not only 
protects from oxidation but also reduces the particle size when compared to others methods 
in the presence of oxygen.105 The low temperature used (80 ºC) was higher enough to prevent 
the production of iron oxide-hydroxide (FeO(OH)·nH2O) that can be easily converted to -
Fe2O3 (maghemite). 80 ºC is low reaction temperature when compared to another methods 
such as thermal decomposition, solvothermal or hydrothermal synthesis.135  
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Table 3.1 Possible oxidations reaction that may occur in aqueous solution when iron (II) and (III) are present136. 
 
The alkalization of the reaction was carried out through the addition, in excess, of a weak 
base (NH4OH) instead of a strong base such as NaOH. The weak base provides a stable 
concentration of OH- in the whole reaction instead of high concentration of OH- in the 
beginning of the reaction.83 Because of the constant concentration of the OH- in the solution, 
the solution is far from the isoelectric point, which is at pH 3.5, (Figure 3.17). So, the 
electrostatic forces between growing particles prevent their aggregation and the resulting 
particles are smaller,137 with a higher crystallinity and saturation magnetization (Ms) than if 
it was used a strong base.83 So, the use of a surfactant during their synthesis to make the 
particles away from each other is not really needed with this method. However, after the 
synthesis, the need to remove the chlorides and ammonia ions from the solution made by 
washing the NPs with water, which neutralizes and approached the pH of the solution to the 
isoelectric point, thereby facilitating the aggregation of them. 
The produced NPs are presented in Figure 3.1. The black colour suspensions settle in a 
relative short time, which demonstrates the high degree of aggregation of the NPs (which 
was later confirmed by TEM, in Figure 3.5. The magnetic behaviour of the particles was 
tested initially with the help of a permanent magnet. (Figure 3.1b). As it possible to see, the 
particles strongly are strongly attracted to the magnet, but soon as the magnet was removed, 
it was observed that the particles recovered their initial properties. 
 
 Reaction Phase 
(01) Fe2+ + 2Fe3+ + 8OH– → Fe3O4 + 4H2O Magnetite 
(02) 2Fe3O4 + ½ O2 → 3 γ-Fe2O3 
Maghemite 
(03) 2Fe3+ + 6OH– → γ-Fe2O3 + 3H2O 
(04) 2Fe(H2O)6
3+ → α-Fe2O3 + 6H+ + 9H2O Hematite 
(05) Fe3O4 + ¼ O2 + 9/2 H2O → 3Fe(OH)3 
Hydroxide de Fe (III) 
(06) Fe3+ + 3OH– → Fe(OH)3 
(07) Fe3+ + 3OH– → α-FeOOH + H2O 
Goethite 
(8) Fe3+ + 2H2O → α-FeOOH + 3H+ 
(9) Fe2+ + ¼ O2 + ½ H2O → Fe3+ + OH– Oxidation de Fe2+ para Fe3+ 
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Figure 3.1 (a) Image showing the response of the produced MNPs in the absence of magnetic field (B=0) and 
(b) in the presence of magnetic field (B>0). 
 
Although chemical precipitation is a facile and rapid method of synthesis, magnetite have 
low stability in aqueous medium.100 Due to the oxygen present in the water, is able to be 
oxidized leading to the formation of other iron oxide like maghemite, goethite or iron 
hydroxide (III)136 (Table 3.1). After 8 months reserved in water, the same MNPs once had 
black colour, now shows a brownish colour, characteristic of one of other possible iron 
oxide: the maghemite. In Figure 3.2, it is possible to see the change in colour of fresh 
synthesized iron oxide NPs, with black colour (a) designated as Fresh NPs, and after eight 
months aging, designated Old NPs (b), with a brownish colour. This change in colour is due 
to the oxidation.  
 
                    
Figure 3.2 Experimental appearance of iron oxide MNPs: (a) Fresh MNPs; (b) Old MNPs after 8 months of 
aging. 
 
The Rietveld refinement of Fresh and Old NPs is presented in Figure 3.3. The main peaks 
are observed to match with the Bragg reflection planes of the cubic crystal structure of 
magnetite which is confirmed by JCPDS card no.: 88–0315. In the case of Old particles more 
than one phase was found, as it was suspected from the brownish colour. The phases that 
were identified were magnetite and iron hydroxide (III).  
 
(a) (b) 
(a) (b) 
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Figure 3.3  Results of the Rietveld refinement of the X-ray diffraction patterns for synthetized iron oxide MNPs: 
(a) Fresh NPs, where the blue line represents the Bragg position; (b) Old NPs where orange line represents the 
Bragg position of two phases: magnetite (blue) and iron hydroxide (green). 
 
The easiness of oxidation of the magnetite NPs makes very difficult to synthesize and 
stabilize pure magnetite,54,82,138 being in most of the cases, a mixture of magnetite and 
maghemite that is obtained.138 Mӧssbauer spectroscopy is the only technique, which could 
identify the crystalline phase composition of different iron oxides. But it was not possible to 
collect this data. Then, when the refinement says it is only present one phase and corresponds 
to the magnetite phase, it is possible that this is not true. For example, the standard diffraction 
pattern for magnetite (JCPDF 01-088-0315) and maghemite (JCPDF 00-039-1346) powders 
are compared in Table 3.2. They are very similar, with maghemite values slightly higher 
than magnetite, demonstrating the difficulty to distinguish between two similar phases like 
as magnetite and maghemite. Both of them have spinel structure with very closely Bragg 
position. From the comparison between the Old and Fresh NPs with the provided JCPDF 
data, it is possible to see that both NPs have 2-θ values closer to the JCPDF of magnetite 
than to maghemite. This may indicate that magnetite is present in both, and in greater 
quantity than maghemite, but still, is just a qualitative information. Other techniques as FTIR 
and TGA were be performed to strength this information once the only technique could not 
be performed.  
The average crystallite size was determined by the Scherer’s equation (3.1):139 
𝜏 =
 𝐾𝜆
𝛽cos (𝜃)
 
where K is the grain shape factor, λ is the incident X-ray wavelength, β is the full width at 
half-maximum (in radians) of the highest intensity peaks (311) and θ is the corresponding 
diffraction angle. Fresh NPs have average particle size of 14.7 nm and Old NPs have 11.2 
nm, which is in agreement with results published in literature.133 Both NPs are below the 
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critical size for SPM NPs (<20 nm). The broadness of the reflexion peaks (full width at half 
maximum) of the X-ray diffractograms is indicative of the nanometer size of the synthesized 
NPs (Figure S1 in annex). 
The size of the MNPs developed in this study is suitable for medical applications.  
  
Table 3.2 Position of the main diffraction peaks of the synthesized Old and Fresh MNPs and  comparison to 
the data found in the JCPDF database concerning magnetite (Fe3O4) and maghemite (γ-Fe2O3).138  
Old Fresh 
Fe3O4 
01-088-0315 
γ-Fe2O3 
00-039-1346 
Old Fresh (h k l) 
2-θ I(f) 2-θ I(f) 2-θ I(f) 2-θ Fe3O4 Fe2O3 Fe3O4 Fe2O3  
30.18 43.24 30.06 37.05 30.16 28.8 30.24 0.02 0.06 0.10 0.18 (2 2 0) 
35.46 100 35.50 100 35.52 100.0 35.63 0.06 0.17 0.02 0.13 (3 1 1) 
37.12 21.62 37.07 16.39 37.16 7.9 37.25 0.04 0.13 0.09 0.18 (2 2 2) 
43.10 31.35 43.16 30.49 43.17 20.7 43.28 0.07 0.18 0.01 0.12 (4 0 0) 
53.70 23.24 53.54 17.38 53.56 8.7 53.73 0.14 0.03 0.02 0.19 (4 2 2) 
57.18 44.86 56.98 31.75 57.10 28.7 57.27 0.08 0.09 0.12 0.29 (5 1 1) 
62.78 62.16 62.48 41.97 62.70 37.1 62.92 0.08 0.14 0.22 0.44 (4 4 0) 
 
FTIR measurements were performed to check the chemical bonds in the as-synthesised and 
functionalized MNPs. The spectra of Figure 3.4 shows that Old and Fresh NPs are composed 
of three characteristic bands: a broad band between 3000-3500 cm-1 related to the -OH 
stretching vibration modes of water, a band at ~1630 cm-1 attributed to the O-H stretching 
vibration mode and a band at ~530 cm-1 which is characteristic of the Fe-O stretching 
vibration.41,73,100  By analysing comparably the FTIR spectra of Old and Fresh MNPs (Figure 
3.4), it is possible to suspect that the Old MNPs consist in a mixture of magnetite and 
maghemite, since the band located at 528 cm-1 is not as sharp as the one displayed by the 
Fresh MNPs, which should be mainly formed by magnetite.138 
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Figure 3.4  FTIR spectra of Old (continuous line) and Fresh (dotted line) synthetized iron oxide  MNPs.  
 
The size and morphology of the Fresh MNPs were evaluated by TEM, which is presented in 
Figure 3.5. The Fresh magnetite NPs were observed to be nearly spherical in shape and 
highly aggregated (as already mentionated). The particle size distribution histogram, shown 
in Figure 3.6 has been constructed from the image analysis of the Figure 3.5(a) using ImageJ 
software.140 The mean particle size calculated is 9.81 nm with a standard deviation of 2.87 
nm and a standard error of the mean as 36.1%. The particle size distribution observed from 
TEM is in the same range of crystallite size determined from the refinement of the X-ray 
diffraction. The differences may be assigned to huge difficulty in measuring the particles 
due to the high aggregation degree.  
The lattice fringes of the produced MNPs can be seen in Figure 3.5b), which demonstrate 
that synthesized nanoparticles are crystalline. 
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Figure 3.5 TEM images of fresh MNPs synthetized Fresh MNPs: a) overall view demonstrating the huge 
aggregation; b) the lattice fringes of the planes of the iron crystal structure. 
 
 
 
Figure 3.6 Size histogram showing the average diameter (9.81 nm) of the synthesized nanoparticles.  
 
3.2 Linkage agents to enable the MNPs coating 
 
Once we are dealing with very small particles, the high surface area makes them more 
susceptible to oxidation processes that can occur on their surface.141 The coating of MNPs 
is a great solution to avoid oxidation. More, human body is composed by more than 70% of 
water, which means having a neutral pH. The produced MNPs are unstable in neutral pH (as 
it was observed in the Zeta Potential measurements, see Figure 3.17) and aggregates to be 
more stable, resulting in large agglomerates of NPs. Moreover, aggregated MNPs are not 
very effective in producing heating. So, to significantly improve the heating efficiency, 
disaggregation is need, because large hydrodynamic sizes slow down the Brownian 
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relaxation diminishing the heating efficiency. So, the particles must be disaggregated to 
achieve faster relaxations.61 
The type of coating of the NPs is an important factor, because the MNPs can enter in the 
body by different ports, circulating through the lymphatic system and/or the bloodstream, 
either freely or after being phagocytosed.68 So, it is important to have a stable coating, able 
to remain on the particles, even when they are exposed to interaction. The biocompatible 
coating proposed in this Thesis involves  the biopolymer chitosan and to promote strong link 
of chitosan in to the iron oxide NPs it was used two linkages molecules: the dopamine and 
the caffeic acid. 
 
3.2.1 Linking with Dopamine 
 
Xu et al.81 reported the use of dopamine, a natural molecule, as an attractive ligand 
to hydrophilic NPs of iron oxide, due to the strong interaction between vicinal diol groups 
to the iron oxide surface. In addition to be a stable to anchor, dopamine can work as a 
bridging ligand bonding other molecules through the amine groups.81,127,142 
The FTIR spectra of dopamine (DOPA), iron oxide NPs functionalized with dopamine 
(F.DOPA) and MNPs are presented in Figure 3.7.  Dopamine showed at 1616 cm-1, 1497 
cm-1, 877 cm-1 (primary amine bending) and at 3336 cm-1 (stretching modes),143 at 1471 cm-
1 and at 3036 cm-1 (aromatic C=C symmetric stretching), at 598 cm-1 (C-C-C symmetric 
bending) and at 2953 cm-1 (C-H symmetric stretching).144  
In the spectra of F.DOPA the characteristic peak of Fe-O at 533 cm-1 still present and the 
appearance of peaks at 1600 cm-1, 1485 cm-1 and 872 cm-1 (primary amine bending) confirms 
the link between the MNPs and dopamine.145 Further, the appearance peaks in F.DOPA 
spectra  at 1398 cm-1 (hydrogen stretching vibration), at 2801 cm-1 (skeleton stretching 
vibration of benzene ring),86 at 1031 cm-1 (stretching vibration of O–H), at 2847 cm-1 
(stretching vibration of C–H), the broad band at 3300–3450 cm-1 (representing the stretching 
vibration of –OH),110 at 693 cm-1 (C-C-C symmetric bending), at 1089 cm-1 (C-C-H 
symmetric bending)144 supports even more that the conjugation of dopamine onto iron oxide 
was reached. 
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Figure 3.7 FTIR spectra of pristine Dopamine (DOPA), Fresh Fe3O4 and Fe3O4 conjugated with dopamine 
(F.DOPA). 
 
3.2.2 Addition of Genipin 
 
Genipin (GP), present in Figure 3.8, is a natural crosslinker with high biocompatibility and 
stability to heat, pH and light than the most used synthetic crosslinking agent 
glutaraldehyde.60,146 Further, it was reported that GP might be about 5000–10.000 times less 
cytotoxic than glutaraldehyde.125,147 Additionally, can naturally and effectively react with 
primary amino groups.60 Furthermore, it was reported that the reaction of the GP with the 
amino groups of chitosan, make them insoluble to acidic medium.147,148 
 
Figure 3.8 Chemical structure of genipin. 
 
FTIR spectra of the tethering of GP into F.DOPA (F.DOPA.GP) is present in Figure 3.9. 
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Figure 3.9 FTIR spectra of genipin (GP), F.DOPA and F.DOPA conjugated with GP (F.DOPA.GP). 
 
The assignments of the bands in the GP spectra presented in Figure 3.9 were as follows: at 
1679 cm-1 (C=O stretching vibration of the ester),149–151 at 1109cm-1 (C-O-C stretch),151 at 
3388 cm-1 (associate O–H stretching vibration), at 3207 cm-1 (C=C–H stretching 
vibration)149 and at 1621 cm-1 (C=C stretching vibration of the ring).149,151  The band at 1417 
cm-1 was assigned to a ring stretching mode in the GP molecule.146  
When GP was bounded to the F.DOPA NPs, the peaks at 1679 cm-1, the peaks at 1109 cm-1 
and at 1621 cm-1 disappeared in cross-linked NPs of F.DOPA. The appearance of a weak 
absorption at 1584 cm-1 (C=C stretch of alkene) and at 1719 cm-1 (corresponding C=O 
stretch) revealed the ring-opening. The appearance of a peak at 1452 cm-1 (C=O stretch of 
carboxylic ion)151 and the disappearance of the peak at 1442 cm-1 (stretching of methyl group 
of GP)150 suggest that the ester groups were converted into carboxylic ions. A decrease in 
the characteristic peak derived from amine (-OH) stretch between 3500-3200 cm-1 152 
presents in GP FTIR spectra after crosslink into F.DOPA NPs was notice. More the aromatic 
peaks of dopamine are notice and shifts to lower values at 3027 and 2920 cm-1.  
 
3.2.3 Linking with Caffeic Acid 
 
Caffeic acid (CA) is an organic compound classified as hydroxycinnamic acid153 that have 
14attracted attention in the last few years because of their biological properties as 
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antioxidant, immunomodulatory, anti-inflammatory, and anticarcinogenic activities.85,154,155 
Further, have a structural similarity to dopamine as it possible to see in Figure 3.10.  
 
             
Figure 3.10 Chemical structure of caffeic acid and dopamine.    
 
FTIR spectra of CA, iron oxide MNPs conjugated with CA (F.CA) and iron oxide MNPs are 
presented in Figure 3.11. Three characteristic peaks in CA spectrum are shown: at 1616 cm-
1 (C=O stretching of free carboxylic acids), at 1598 cm-1 (asymmetric COO- stretching) and 
at 1447 cm-1 (symmetric COO- stretching). Further at 2983 cm-1 (asymmetric CH2), at 2832 
cm-1 (symmetric CH2 stretching) and the band at 3400 – 3200 cm-1 (carboxylic acid -OH 
stretching).  
The functionalization onto the iron oxide of CA was essentially made by the catechol group. 
The strong peak at 1598 cm-1 of pure CA, which points out the C=O vibration (symmetric 
stretching) from the COOH, remains but shifts to 1577 cm-1 and becomes weaker in the F.CA 
sample. A large and intense band between 3400-3200 cm-1 that could be assigned to the 
structural OH groups as well as to the traces of molecular water are present.84,153,156 The 
peaks between 1200–1500 cm-1 and 800–850 cm-1 can be assigned to the presence of caffeic 
acid aromatic ring. The aromatic ring C=C stretching is within the 1450–1600 cm-1; C-O/C-
C stretching vibrations are within the 1200–1300 cm-1.126 
Additionally, it is possible to see the metal–oxygen band at 537 cm-1 corresponding to 
intrinsic stretching vibrations of the iron oxide. Thus, concluding that the functionalization 
was achieved. 
 
 
Dopamine Caffeic acid 
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Figure 3.11 FTIR spectra of pure Caffeic acid CA, Fresh iron oxide MNPs and when conjugated with caffeic 
acid (F.CA). 
 
3.2.4  Thermogravimetric analyses of the functionalized particles 
 
TGA provides additional quantitative evidence of the coating of the MNPs surface.18,73 By 
this technique it is possible to determine the thermal stability of the coated MNPs.17,65,73 
In Figure 3.12 is possible to see the differences in thermal behaviour during the analysis. As 
expected, the MNPs were not degraded from room temperature until 400 ºC.100 Only the 
organic part of the coating suffer degradation. Until 150 ºC, the weight losses occurred are 
attributed to the removal of physically and chemically adsorbed water.17,71,84,153 Above this 
temperature the MNPs can lose the hydroxyl groups present at the surface and then organic 
groups start to be degraded. 
The Old and Fresh MNPs have different behaviours as expected from the distinct degree of 
oxidation. The Old MNPs show about 19% of total weigh, corresponding to near only 4.5% 
of water loss and about 15% of weight loss between 180ºC and 260ºC assigned to release of 
hydroxyl groups from the surface of the particles. The total weight loss observed in Fresh 
NPs were only 3.5%, where 2.2% corresponds to water loss up to 150 ºC. This results are in 
agreement with others of literature.17,73 The 0.01% of loss above 400ºC observed in Fresh 
MNPs may be due to some oxidation in the surface of the MNPs of magnetite that occurs in 
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the presence of air atmosphere (it is possible to see some endothermic peak from 400 ºC to 
600 ºC). Further, comparing the Old and Fresh MNPs, the Old MNPs do not have 
endothermic process at high temperatures, probably because the Old MNPs surface was 
already oxidized (passivated). So, it is possible to conclude that in Fresh NPs the amount of 
magnetite is greater than in Old NPs. 
Regarding to the functionalized NPs, namely the F.CA, it is possible to see that caffeic acid 
starts to decompose at 200 ºC.84,153 There are two exothermic peaks, a great one about 200 
ºC and at 300 ºC.84,153 It is possible to observe a small endothermic peak about 400 ºC. The 
greater loss of organic mass observed in Old MNPs should be the result of high yield of the 
coating reaction with consequent better coverage of the NPs surface.  
The decomposition of dopamine have two major stages, one at 200 ºC, which is due to the 
decomposition of ethylamine arm NH2
30 and another at 500 ºC concerning the decomposition 
of the aromatic ring.  Relatively to the F.DOPA NPs, it is possible to see that the differences 
between Old and Fresh NPs spectra are bigger than in the case of caffeic acid. The Fresh 
NPs after reacting with dopamine seem to have a TGA curve very similar to the one non-
oxidized pure particles. The Old F.DOPA seems to have a higher content of DOPA ligand 
that the Fresh F.DOPA. The first weight loss occurs at 40 ºC (which corresponds to water 
loss) and then, in the Old NPs we have a mass loss at about 200ºC, which is the same range 
of temperature where the dopamine stars to decompose. The release of hydroxyl groups at 
the surface at the iron oxide NPs also happen in this range of temperatures. Observing the 
peaks, we can assume that the weigh losses are not only caused by dopamine decomposition 
but also results from the decomposition of oxidation moieties losses from the iron oxide, 
once has the same behaviour of Old MNPs. 
More, the incorporation of the respective DOPA functionalization did not seem to avoid the 
oxidation of the particles or they were not fully covered by DOPA. The continuous variations 
in decomposition on the functionalized samples indicate that the bonds between the organic 
material (caffeic acid and dopamine) and the core of iron oxide are of a chemical nature, 
stronger than physical bonds. Therefore, this functionalization is stable and adequate to 
biomedical applications.30 
Table 3.3 shows the percentages of mass losses observed in the TGA analyses for the Fresh 
and Old iron oxide and when linked with CA and DOPA 
 
RESULTS AND DISCUSSION 
 
54 
 
 
 
Figure 3.12 TGA analysis of a dried samples of Fresh and Old iron oxide; and when both (Fresh and OLD 
MNPs) conjugated with dopamine (DOPA) and caffeic acid (CA); and the pure DOPA and pure CA. 
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Table 3.3 Summary of the percentage of mass losses during the TGA analysis observed for the Fresh and Old 
NPs and when conjugated with DOPA and CA 
 
 
 
 
 
 
 
 
3.2.5 Chitosan coating 
 
The MNPs were coated with chitosan polymer aiming to protect the iron oxide core and 
maximizing its stability. The bonding between chitosan and the respective binders were 
confirmed by FTIR measurements. 
 
3.2.5.1 Coating F.DOPA.GP MNPs with chitosan  
The coat of chitosan to the MNPs conjugated with dopamine and tethering with genipin was 
confirmed by FTIR. The Figure 3.13 shows the FTIR spectra of the chitosan (CS) and MNPs 
of F.DOPA.GP and coated with CS (F.DOPA.GP.CS).  
In the CS spectra were found bands at 1645, 1574 and 1316 cm-1 which were assigned to the 
(C=O stretching (amide I)),101,157 (N-H bending (amide II))101,147,157 and (C-N stretching 
(amide II)) of the residual N-acetyl groups, respectively.101,157 The peaks at 1376 cm-1 were 
attributed to (C-O-H stretching) of a primary alcoholic group in chitosan. The absorption 
bands between 1000-1100 cm-1 were described to (C-O) and (C-N) stretching vibrations, and 
(C-C-N bending vibrations). The broad bands between 3000 - 3600 cm-1 were related to the 
hydroxyl groups mainly from water which probably overlaps the amine stretching vibrations 
(N-H) in the same region.147,150,157 Significant absorption peaks at 895 and 1150 cm-1 
appears, which corresponds to the C-O linkage of saccharide structure of glucosamine ring.  
One of the most important changes is evident in the reduction of the carbonyl group of the 
GP at 1719 cm-1, which reacts with the primary amine in chitosan to form an amide, is 
Temperature 
(ºC) 
FRESH MNPS 
% weigh loss 
OLD MNPS 
% weigh loss 
 F F.DOPA F.CA F F.DOPA F.CA 
> 150 2.21 2.25 1.48 4.43 1.46 0.95 
150-400 1.25 1.77 3.77 14.14 26.39 6.83 
< 400 0.01 0.54 0.401 0.75 6.44 0.24 
Total 3.47 4.56 5.67 19.32 34.29 8.02 
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indicated by the growth of the absorption band at 1600 cm-1. 147,158 The increase observed in 
the peaks at 1377 cm-1 (C-N stretching vibrations),147 the appearance of characteristic peaks 
of (NH2 asymmetric stretching) at 3407 cm
-1 158 prove that chitosan has been reacted with 
the ligands at the NPs surface 
 
 
 Figure 3.13 FTIR spectra of chitosan (CS), F.DOPA.GP and F.DOPA.GP coated with CS. 
 
3.2.5.2 Coating of the F.CA MNPs with chitosan  
The coat with CS onto functionalized NPS with caffeic acid (F.CA) was tested by two 
different routes: using EDAC chemistry through the creation of amide bonds between a 
carboxylic acid group in CA and a primary amine group in CS and through (CAN). The 
successful conjugation of CS onto the F.CA NPs was confirmed by FTIR. The Figure 3.14 
shows the FT-IR spectra of raw CS alone, F.CA and after the coating with CS using the 
EDAC and CAN procedures to get the coating. It is possible to see that typical bonds of 
chitosan are present in both spectra. The C=O peak at 1577 cm-1 present in F.CA spectrum 
disappeared in the both spectra after the coat with CS (via CAN and via EDAC), confirming 
the successful coupling between the carboxylate groups of CA and the amino groups of 
CS.156 No band appeared at 1730 cm-1 in both spectra (as it evidenced by the circle), 
indicating that no ester bond formed between hydroxyl groups of chitosan and carboxyl 
groups of phenolic acids.101The broad absorption peaks in the range of 3000–3450 cm-1 
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observed in CAN and EDC spectra are due to the chitosan OH groups stretching overlapping 
the N-H stretching.40,85 The bands related to the C-O-C bridge are located at 1152/1091cm-1 
(anti-symmetric stretching of C-O-C bridge). At 1028 cm-1 (skeleton vibration involving the 
C-O-C stretching bands)85,125 and at 823/814 cm-1 (C-O-C stretching of the glycosidic 
linkage)85 of CAN and EDAC respectively. Vibration modes at 1419/1429 and at 1316/1321 
cm-1 assigned to O–H (originating from CS)157 are presented in CAN/EDAC. The absorption 
decrease associated with protonated glucosamine residues of chitosan at 1326 and 1427 cm-
1 indicated a covalent linkage between phenolic acids and the amino groups of chitosan.101 
The band at ~1060 cm-1 is attributed to the C-N stretching vibration mode. Additionally, the 
second band of the amide II (usually found around 1574 cm-1) disappeared and a new band 
at ~1550/1541 cm-1 appeared which corresponds to the N-O asymmetric stretching vibration 
mode, confirming the ionic bond between chitosan and CA85 in the spectra of CAN and 
EDAC respectively. The band at 528 cm-1 in CAN spectrum and at 536 cm-1 in EDAC 
spectruma is attributed to Fe-O stretching vibration mode related to the presence of iron 
oxide.  
 
 
Figure 3.14 FTIR spectra of the MNPs functionalized with CA, and coated with chitosan per two different 
methods: CAN and EDAC. 
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3.2.6 Thermogravimetric Analyses of chitosan coated MNPs 
 
Figure 3.15 show the results of the TGA analyses for the samples coated with chitosan and 
the chitosan used for the coating. 
TGA of pure CS exhibited two distinct stages. The first weight loss of ~13% observed up to 
150 ºC was due to loss of water from the polymer composites. The second one, between 150 
ºC and 400 ºC is ascribed to a complex process including dehydration of the sugar rings, 
depolymerization and decomposition of the acetylated and deacetylated units of the polymer. 
This complex process represented about 47%. As compared to CS, CAN and EDAC have 
two exothermic peaks in the same temperature regions. The first loss, up to 150ºC correspond 
to the water loss. The second one, is due to the degradations of the grafted products (CA and 
CS). In addition, differential thermogravimetry (DTGA) curves showed that the temperature 
for the rapidest weight losses of chitosan appeared at 297 ºC in CAN at 257 ºC and in EDAC 
at 267.3 ºC. This indicates that the thermal stability of CS was reduced after coating. These 
results are consistent with others studies. In general, the introduction of functional groups 
can result in decreasing of thermal stability.101 The thermal stability of EDAC was higher 
than CAN. This difference may also be due to a higher amount of coating present in the 
EDAC sample (11.6%) than in the CAN sample (7.3%).  
Table 3.4 shows all the percentages of weight losses observed in TGA analysis of the 
samples up to the coating with chitosan. 
 
Table 3.4 Summary of TGA percentage of weight losses of all samples. 
Temperature 
(ºC) 
 % Weight losses 
 F F.DOPA F.CA CAN EDAC F.DOPA.GP.CS CS 
> 150 22.1 2.25 1.4 1.89 1.93 0.00 12.58 
150-400 1.25 1.77 3.77 5.21 9.58 5.93 46.96 
< 400 0.01 0.54 0.41 0.2 0.07 10.75 28.17 
Total 3.47 4.56 5.67 7.30 11.58 16.68 87.71 
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Figure 3.15 TGA analysis of the coated with chitosan of the Fresh MNPs conjugated with caffeic acid using 
cerium ammonium nitrate (IV) (CAN) and using EDAC chemistry (EDAC); and the MNPs coated with 
chitosan conjugated with dopamine and genipin (F.DOPA.GP.CS) and the raw chitosan (CS). 
 
TEM images of the coating with chitosan is shown in Figure 3.16. All the samples 
maintained their original type spherical shape and the coated provide by the CS is very well 
observed (evidenced by arrows). There is a huge difference in aggregation in uncoated and 
coated MNPs, which decreases immensely after the functionalization with ligands and with 
chitosan. In the case of the NPs functionalized with dopamine and genipin before the coating 
with chitosan, the level in aggregation seriously decrease when compared with the initial 
NPs. Further, it appears to have a more proportional coating along the NPs with this method 
than EDAC or CAN. Still, by all methods the coating with chitosan was achieved. However, 
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some optimization is need in the case of EDAC and CAN. There are some NPs that seem to 
have less or no coating at all. It is possible to see that the average particle size after the coat 
is much higher than initial NPs.   
 
   
  
Figure 3.16 TEM images of: (a) uncoated MNPs; (b) MNPs functionalized with dopamine and with genipin 
and coated with chitosan (F.DOPA.GP.CS); (c) MNPs functionalized with caffeic acid and coated with 
chitosan via EDAC; d) MNPs functionalized with caffeic acid and coated with chitosan via CAN. The arrows 
evidence the coat of chitosan. The circle evidence the absence of the coat. 
 
3.2.7 Zeta Potential and Hydrodynamic Diameter of funcionalized and coated MNPs 
 
The Zeta Potential values and hydrodynamic diameters of some of the NPs synthesized with 
respect to pH 2 to 12 are shown in Figure 3.17 and Table 3.5, respectively.  
a) b) 
c) d) 
20 nm 
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As it possible to see in Figure 3.17, the Zeta Potential of the NPs ranged from -40 eV to 40 
eV. In physiological pH, the zeta potential was about -17 mV, -30 mV and 33 mV in Fresh 
MNPs, F.CA and F.DOPA respectively. These results show the increase in stability after the 
conjugation.  
The isoelectric point (PI) for MNPs was found to be around 3.5 and possess negative charge 
at physiological pH. These observations are in agreement with other literature as (17). When 
dopamine was added to the particles, this value shift to 9.3. The reactions of the MNPs with 
CA, results in a shift of the P.I. value to 4.5. Through observation on these results of the Zeta 
Potential of F.DOPA and F.CA samples are more positive in the range of pH 2–4.3 and more 
negative after pH 10, in comparison to the Fresh un-conjugated MNP. This indicates that the 
positive charges on the coated NPs increase with a decrease in pH and the negative charges 
on the coated NPs increase with increasing in pH. Proving by this way that the particles were 
functionalized. These results indicate that the functionalization with DOPA and CA can 
provide a steric barrier between the MNPs particles when pH value of the medium is acidic 
or basic, thus decreasing the agglomeration of the MNPs. The coverage provided by the 
functionalization on the unconjugated MNPs surface can stabilize the particles in water 
media. Although, the MNPs conjugated with dopamine shows a better colloidal stability in 
acid media than bare Fe3O4 and when conjugated with CA. The fact that F.DOPA is much 
more positive in the range of pH 2 up to pH 10 than Fresh MNPs and F.CA allow 
crosslinking with GP in more individualized was because of a greater steric barrier. But, 
when the GP is added, their stability decrease. This proves that the crosslinking occurred 
because adding the GP to the F.DOPA the results where similar to the F.CA sample. This is 
because both have free OH- in their structure. However, in the F.DOPA.GP analysis the 
stability is lower than in the F.CA sample in acid and neutral pH, being identical in high pH. 
This is probably because the F.DOPA.GP do not have much charge, being instable and 
allowing aggregation of the MNPs. 
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Figure 3.17 Zeta Potential of the initial MNPs (F) and when functionalized with dopamine (F.DOPA) and 
crosslinked with Genipin (F.DOPA.GP) and with caffeic acid (F.CA). 
 
The hydrodynamic sizes of Fresh MNPs and functionalized NPs were measured using 
dynamic light scattering (DLS). Table 3.5 shows the hydrodynamic diameter distribution of 
bare and capped MNPs in filtered water. The density of the polymeric structure can affect 
the properties of the composites NPs.100 The particle size measurements do not match with 
the crystallite size calculated from XRD pattern, confirming the aggregation in the MNPs 
and the instability of the fluid.133 Especially when close to their respective PI values, where 
the MNPs showed highest hydrodynamic diameters due to highest degree of agglomeration. 
The uncoated MNPs have larger size due to higher degree of agglomeration and 
consequently show lager hydrodynamic diameter than the coated ones. However, the same 
way as happened with the analyses of TEM images. The mean diameter of the MNPs coated 
with chitosan increase, proving that the coating with chitosan was achieved. 
Polydispersity degree indices (PDIs) lower than 0.25 shows a monomodal distribution.71 The 
stirring the mixtures before the analysis does not influence size of MNPs, since the MNPs 
settle during the analysis whatever the time during which the solution was stirred. 
Although knowing that the hydrodynamic size obtained from DLS were not correct, it is 
possible to see a decrease on the diameter after reaction of the MNPs with DOPA. This 
decrease did not happen with CA, thereby highlighting that dopamine is a better option 
concerning to the dispersion of particles, leading to high colloidal stability. After the addition 
of GP to the F.DOPA NPs, a huge increase in the diameter was noticed by the DLS analysis. 
This is probably due to polymerization of GP. However, the addition of GP particles did not 
contribute to the increase in the colloidal stability. Moreover, the colloidal stability at acidic 
pH decreases to levels similar to unconjugated NPs as it is possible to see in Figure 3.17. 
The polydispersity (PDI) is a measure of the degree of non-uniformity, that is influenced by 
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the size, charge, magnetic field distribution, pH and coating.9 A value between 0.1 and 0.4  is 
indicative of an intermediate, moderately polydisperse distribution type.159 
 
Table 3.5 Hydrodynamic diameter of the iron oxide MNPs and with some of MPS with the ligand and the coat 
of chitosan. Z- represents the average size; Std - represent the standard deviation; d – represents the diameter 
in nm. 
AMOSTRA pH Z stdv Pdi stdv 
Number Mean Intensity Mean Volume Mean 
d std d std d std 
 Fresh 6.22 345 1,127 0,47 0,067 137 7,1 467 93,88 665,2 210,4 
 F.DOPA 4.99 146.8 0.4619 0.215 0.015 72.71 8.655 225,9 45.5 248.8 97.39 
 F.DOPA.GP 5.90 346.7 25.1 0.243 0.011 265.9 21.21 354,3 29.3 385.2 42.57 
F.DOPA.GP.CS 5.78 433.9 2.219 0.465 0.028 146.0 22.04 404.1 43.26 469.3 106.2 
            
Fresh 6.22 345 1,127 0,47 0,067 137 7,1 467 93,88 665,2 210,4 
 F.CA 5.56 151.6 1.097 0.194 0.007 84.4 1.141 235,8 6.976 292.2 22.9 
 EDAC 5.62 401.5 5.009 0.39 0.016 158.6 9.536 566.4 47,04 835.8 99.67 
 
It is possible to see that at about neutral pH, the functionalization decrease the hydrodynamic 
diameter both for NPs of F.DOPA and F.CA. Observing the results of intensity mean of 
before and after the add of the functionalization agents, is clear that the larger particles have 
decreased and were similar in both of them. This proves that the functionalization occurred 
as well as steric barrier that was provided.  
The addition of the GP as tethering agent in the F.DOPA NPS resulted in an increase of Z-
average diameter of the NPs to values similar to the iron oxide MNPs. But, a deeper look to 
the number mean, intensity mean as well volume mean, is observed that these do not increase 
to similar values of the iron oxide MNPs. This strength the steric barrier caused by the adding 
of the dopamine to the iron oxide. As genipin can easily bond amine groups of DOPA, and 
eventually reacted with other GP molecules148 this results in a considerable increase of the 
hydrodynamic diameter.  
 The addition of CS to the functionalized NPs resulted in an increase of the hydrodynamic 
diameter, (more notice in the F.CA NPs) which confirms the coverage of the particles with 
chitosan, which is a biopolymer with a significant long chain.   
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3.2.8 Magnetic Characterization 
 
The curves resulting from the study of the magnetization as a function of temperature (ZFC 
and FC) and of the magnetization as a function of the magnetic field for the iron oxide MNPs 
are shown in Figures 3.18 (Fresh and Old) and 3.19 (F.CA; F.DOPA; CAN; EDAC; and 
F.DOPA.GP.CS). The observation of these curves allows verifying a clear 
superparamagnetic behaviour of the MNPs at room temperature. 
In general, the magnetic behaviours of the different samples are similar as well as the 
saturation and coercivity magnetization values. All samples exhibit ferrimagnetic behaviour 
as expected for magnetite type samples, displaying a high slope at low fields and saturating 
for external fields above 1 T. The coercivity and the remanent magnetization are very small. 
The analysis of the ZFC curves in Figures 3.18 and 3.19 shows a continuous increase up to 
250 K indicating that the Fresh MNPs blocking temperature is above this temperature. This 
is consistent with the size of the magnetic nanoparticles (around 14.7 nm). The amount of 
iron oxide in composite particles was obtained from the corresponding saturated magnetic 
moment at 250 K, assuming the saturation magnetization obtained from the non-
functionalized sample. The concentration of the iron oxide in the dispersions was obtained  
assuming that the density of the particle dispersion was close to one (density of water).  
  
 
Figure 3.18 Magnetization curves as a function of temperature (up to 250 K) measured at 50 Oe, and 
magnetization curves as a function of the applied field of the iron oxide MNPs (Fresh and Old NPs). 
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Figure 3.19 Magnetization curves as a function of temperature (0-250 K) measured at 50 Oe, and as a function 
of the applied field of the F.DOPA, F.DOPA.GP.CS, F.CA, EDAC, CAN. 
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The comparison of the magnetization curves as a function of the temperature in Figure 3.18 
allows to verify that the ZFC and the FC curves in the Old NPs do not touch at high 
temperatures, providing an evidence of the partial oxidation of the iron. The same evidence 
was also verified when caffeic acid was used. In Figure 3.19, it is observed peaks in the ZFC 
curve near 200 ºC, assigned to oxidized magnetite. 
The ZFC and FC curves of F.DOPA close at 250 °C, which indicates that these MNPs are 
the best dispersed, in agree with the Zeta Potential results.  
 
3.2.9 Magnetic hyperthermia measurement 
 
The study of the ability to release energy by the particles when subjected to an alternating 
magnetic field was performed for some sample previously mentioned. As explained above 
the results of these measurements give rise to a temperature vs time plot which provides the 
parameters required for determination of specific loss power (SLP) (Eq. 3.2). In this work 
and in order to determine this value with greater accuracy, the determination of the SLP 
values were determined by the following equation: 
𝑠𝑙𝑜𝑝𝑒 =
∆𝑇
∆𝑡
 
𝑆𝐿𝑃 = 𝑠𝑙𝑜𝑝𝑒 ×
(𝑚𝑔𝑙𝑎𝑠𝑠×𝑐𝑔𝑙𝑎𝑠𝑠+0.3×𝑚𝑤𝑎𝑡𝑒𝑟×𝑐𝑤𝑎𝑡𝑒𝑟)
𝑚𝑁𝑃𝑠
   (Eq. 3.2) 
 
Where ∆𝑇 is the variation of temperature, ∆𝑡 is the time variation (in s), 𝑚𝑁𝑃𝑠 is the mass of 
the sample (in g), 𝑚𝑔𝑙𝑎𝑠𝑠 and 𝑚𝑤𝑎𝑡𝑒𝑟 are the mass of the glass (the quantity that was in 
contact with the sample ≈ 80% of the mass of the botlle) and the mass of water (in g), 𝑐𝑔𝑙𝑎𝑠𝑠 
and 𝑐𝑤𝑎𝑡𝑒𝑟 are the heat capacity of glass (0.2 cal g
-1 ºC-1) and the water (1.0 cal g-1 ºC-1), 
respectively.  The sum of the product of 𝑚𝑔𝑙𝑎𝑠𝑠 and 𝑐𝑔𝑙𝑎𝑠𝑠 with 𝑚𝑤𝑎𝑡𝑒𝑟 and 𝑐𝑤𝑎𝑡𝑒𝑟 
correspond to the value of heat specific capacity, c (in cal ºC). 0.3 represents a factor related 
to heating absorbed by the glass during the measurement. 
In the Figure 3.20 is found the assays performed on distilled water for the synthesized 
samples. In general, experimental values exhibit a progressive increase in temperature at the 
time of the stipulated period (160 s). In order to be able to correctly compare the results 
obtained with the different samples, the SLP values were calculated by equation 3.2. The 
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values obtained are summarized in Table 3.6. As we were measuring composite 
nanoparticles, and the concentration of magnetic nanoparticles was not completely known, 
the mass values were corrected assuming the magnetization of saturation of the pure MNPs. 
The values obtained for the SPL varied between 33 (in the F.DOPA.GP.CS) to near 55 W/g.  
The value in the obtained with the F.DOPA.GP.CS NPs relatively low in comparison with 
the others NPs could be the result of the some polymerization of the biopolymer CS and GP 
that occurs and trapped f NPs, diminishing their Brownian losses. and These results are quite 
promising as the coating conditions are not yet optimized. 
The comparison of the SLP values obtained with other published values is difficult, since, 
the conditions of measurements strongly influence the results, and the authors do not always 
specify the measurement conditions in detail. On the other hand, factors such as: the applied 
magnetic field (coil used, frequency and current intensity); the magnetic properties of NPs 
(eg, saturation magnetization); the physical properties of NPs (in particular their size and 
dispersion), among other factors, also influence the determined values. 
 
 
 
Figure 3.20 Temperature variation as a function of time for samples synthesized in distilled water when 
subjected to an alternating magnetic field. 
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Table 3.6 Values of the specific absorption rate of the synthesized samples, based on the results obtained. It is 
assumed that the mass of the dispersion is equal to the volume of water. cwater=4.185 (J / g K) and cglass=0.2 (J 
/ g K). 
Sample 
slope 
mglass 
(g) 
mdispersion 
(g) 
cNPs 
(g/ml) 
mNPs 
(g) 
SLP 
(W/g) 
F.DOPA 0.03492 4.4331 2.941 2.76E-03 8.12E-03 54.1 
F.CA 0.02444 4.4694 2.8981 2.02E-03 5.85E-03 51.8 
EDAC 0.00198 4.4581 2.6421 1.55E-04 4.10E-04 54.8 
CAN 0.00425 4.4377 2.7702 3.35E-04 9.28E-04 54.3 
F.DOPA.GP.CS 0.00483 4.4666 3.0105 6.25E-04 1.88E-03 33.0 
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Conclusion 
 
In this work, was synthesized MNPs of iron oxide by coprecipitation. The prepared 
nanoparticles have size of about 14 nm. The average size is in agreement with other 
literature. The result of structural characterization by diffraction of X-rays (the determination 
of the lattice parameter for Rietveld refinement) points to the formation of magnetite iron 
oxide crystallographic phase, although the presence of maghemite cannot be discharged. 
The main objective of this study was to cover the iron oxide NPs with a biocompatible 
polymer, the chitosan through two different molecules (dopamine and caffeic acid) was 
achieved. The link between the iron oxide and the ligands agents was proved as well as the 
disaggregation of the iron oxide NPs. The tethering of the F.DOPA with genipin, was 
accomplished and proved.  The shell of chitosan in the NPs are well observed in the NPs, 
proving that by these agents of functionalization and tethering, it is possible to coat the MNPs 
of iron oxide. All this results were confirmed by FTIR, TGA, TEM and DLS/Zeta Potential. 
The results of measurements of the hyperthermia show good and similar results between the 
different iron oxide coatings. 
In future, the synthesis of iron oxide nanoparticles should be optimized in order to obtain 
more uniform size as well less aggregation, to be possible a more individualized coating.  
The results in magnetization and hyperthermia are similar in the NPs. Test stability of the 
coated NPs should be one of the next steps. 
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Table S1-Additional information about the used reagents. 
Reagent Chemical formula Purity Brand 
2-(N-Morpholino)ethanesulfonic acid 
hydrate  (MES hydrated) 
C6H13NO4S·xH2O 99,5% 
Sigma-Aldrich 
acetic acid CH3COOH ≥99,7% 
ammonium hydroxide  NH4OH 28-30% 
caffeic acid C9H8O4 ≥98% 
chitosan (medium molecular weight)  
deacetylation degree=75-85% 
(C6H11NO4)n -- 
dopamine hydrochloride (HO)2C6H3CH2CH2NH2·HCl 98% 
iron (II) chloride tetrahydrate FeCl2∙4H2O ≥99.0% 
Iron (III) chloride FeCl3 97% 
Isopropyl alcohol C3H8O ≥99,8% 
1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide   (EDC) 
C8H17N3·HCl ≥99,5% 
ethanol C2H6O >99,8% Carlos Erba 
genipin C11H14O5 98% Challenge Bioproducts Co 
N-Hydroxysuccinimide C4H5NO3 >98% TCI 
 
